



## PREFERRED DRUG LIST AND PRIOR AUTHORIZATION CRITERIA

# **The West Virginia Bureau for Medical Services Office of Pharmacy Services**

## **Preferred Drug List and Prior Authorization Criteria**

*This is not an all-inclusive list of available covered drugs and includes only managed categories.  
Refer to cover page for complete list of rules governing this Preferred Drug List (PDL).*

- Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. A current listing of all covered over-the-counter (OTC) products may be found at [the BMS Website](#) by clicking the hyperlink.
- Prior authorization (PA) of any non-preferred agent requires that class criteria, and in some cases drug-specific criteria, be followed unless documentation is provided indicating that the use of these agents would be medically contraindicated. “Exceptions” to the PA criteria should be detailed on the PA form for consideration; these include relative contraindications, such as potential drug-drug interactions, adverse effects, intolerance, and drug-disease interactions.
- Required trials of preferred agents are defined as “failed” or otherwise satisfied only when efficacy has not been observed despite patient adherence to a dose and duration which should have produced therapeutic effects.
- Unless otherwise specified, all requests to “grandfather” existing drug therapy will require clinical reasoning from the prescriber detailing why the patient cannot be transitioned to a preferred agent from the Medicaid PDL. Please note that this requirement includes therapy that may have been previously preferred on the Medicaid PDL but has since changed to non-preferred status.
- The use of pharmaceutical samples will not be considered when evaluating the members’ medical condition or prior prescription history for drugs that require prior authorization.
- Other drug utilization review restrictions may apply, including, but not limited to, therapeutic duplication, drug-drug interaction, ingredient duplication, etc.
- Quantity limits may apply. Refer to the Drug Limits List on [the Bureau for Medical Services \(BMS\) website](#) by clicking the hyperlink.
- Unless otherwise indicated, non-preferred combination products require medical reasoning beyond convenience or enhanced compliance as to why the clinical need cannot be met with a preferred agent or combination of preferred single-ingredient agents containing the same, or similar, active ingredient.
- Acronyms
  - Clinical (CL) – Requires clinical PA. For detailed clinical criteria, please go to the [PA Criteria](#) page by clicking the hyperlink.
  - Non-Reviewed (NR) – Denotes a new drug which has not yet been reviewed by the Pharmaceutical and Therapeutics (P&T) Committee. **These agents are available only on appeal to the BMS medical director.**
  - Automatic PA (AP) – Non-preferred and selected preferred drugs, where indicated, are subject to auto-PA criteria. See PA Criteria column.

<b>CLASSES CHANGING</b>	<b>Status Changes</b>	<b>PA Criteria Changes</b>	<b>New Drugs</b>
ANDROGENIC AGENTS			X
ANGIOTENSIN MODULATORS	X		
ANTIBIOTICS INHALED	X		
ANTICOAGULANTS	X		
ANTICONVULSANTS			X
ANTIEMETICS	X		
ANTIMIGRAINE AGENTS, ACUTE			
ANTIPARASITICS, TOPICAL	X		X
ANTIPSYCHOTICS, ATYPICAL AND COMBINATION	X		
ANTIRETROVIRALS			X
ANTIVIRALS			X
ANTIVIRALS, TOPICAL			X
BETA BLOCKERS			X
BONE RESORPTION SUPPRESSION AND RELATED AGENTS			X
COPD AGENTS			X
CYTOKINE AND CAM ANTAGONISTS			X
DIABETES AGENTS, DPP-4 INHIBITOR			X
DIABETES AGENTS, SGLT2 INHIBITOR	X		
DRY EYE PRODUCTS	X		
DUCHENNE MUSCULAR DYSTROPHY CORTICOSTEROIDS			X
HEART FAILURE TREATMENTS	X		X
IMMUNOMODULATORS, ATOPIC DERMATITIS	X		
OPHTHALMICS ALLERGIC CONJUNCTIVITIS	X		
OPIATE DEPENDENCE TREATMENTS	X		
ORAL AND TOPICAL CONTRACEPTIVES	X		
PLATELET AGGREGATION INHIBITORS	X		
POTASSIUM REMOVING AGNETS	X		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>ACNE AGENTS, TOPICAL<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 30-day trial of one preferred retinoid and two unique chemical entities in two other subclasses, including the generic version of the requested non-preferred product, before they will be approved, unless one of the exceptions on the PA form is present.		
In cases of pregnancy, a trial of retinoids will <i>not</i> be required. For members 18 years of age or older, a trial of retinoids will <i>not</i> be required. Acne kits are non-preferred.		
<b>Specific Criteria for subclass will be listed below. NOTE:</b> Non-preferred agents in the Rosacea subclass are available <u>only on appeal</u> and require at least a 30-day trial of all preferred agents in that subclass.		
<b>ANDROGEN RECEPTOR INHIBITORS</b>		
	WINLEVI CREAM (clascoterone)	
<b>ANTI-INFECTIVE</b>		
clindamycin lotion, medicated swab, solution erythromycin gel, solution	AMZEEQ FOAM (minocycline) CLEOCIN-T (clindamycin) CLINDACIN ETZ KIT, MEDICATED SWAB (clindamycin) CLINDACIN P (clindamycin) CLINDACIN PAC (clindamycin) clindamycin foam, gel dapsone ERYGEL (erythromycin) erythromycin medicated swab EVOCLIN (clindamycin) FABIOR (tazarotene) KLARON (sulfacetamide) OVACE/PLUS (sulfacetamide) sodium sulfacetamide 10% cleansing gel sulfacetamide	
<b>RETINOIDS</b>		
adapalene gel tretinoin cream	adapalene cream, lotion ATRALIN (tretinoin) AVITA (tretinoin) tazarotene cream, foam, gel tretinoin gel tretinoin gel micro	<b>In addition to the Class Criteria:</b> PA required for members 18 years of age or older.
<b>KERATOLYTICS</b>		
benzoyl peroxide cleanser (Rx, OTC), 10% cream (OTC), gel (Rx, OTC), lotion (OTC), wash (OTC)	BENZEFOAM (benzoyl peroxide) BP 10-1 (benzoyl peroxide) BPO (benzoyl peroxide)	

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>COMBINATION AGENTS</b>		
benzoyl peroxide/clindamycin gel (generic DUAC only) clindamycin phosphate/benzoyl peroxide (generic ACANYA) sulfacetamide sodium/sulfur suspension ZIANA (clindamycin/tretinoin)*	ACANYA (clindamycin phosphate/benzoyl peroxide) adapalene-benzoyl peroxide* AVAR/-E/LS (sulfur/sulfacetamide) benzoyl peroxide/clindamycin gel (all generics other than DUAC) benzoyl peroxide/erythromycin benzoyl peroxide/urea clindamycin phosphate/benzoyl peroxide (generic) clindamycin-tretinoin gel* NEUAC (clindamycin phosphate/benzoyl peroxide) SSS 10-4 (sulfacetamide/sulfur) SSS 10-5 foam (sulfacetamide/sulfur) sulfacetamide sodium/sulfur cloths, lotion, pads sulfacetamide/sulfur cleanser, wash sulfacetamide/sulfur wash kit sulfacetamide sodium/sulfur/urea SUMADAN/XLT (sulfacetamide/sulfur) SUMAXIN/TS (sulfacetamide sodium/sulfur) ZMA CLEAR (sulfacetamide sodium/sulfur)	<p><b>In addition to the Class Criteria:</b> Non-preferred combination agents require 30-day trials of the corresponding preferred single agents before they will be approved.</p> <p>*PA required for combination agents with Retinoid products for members 18 years of age or older.</p>
<b>ROSACEA AGENTS</b>		
azelaic acid gel metronidazole cream metronidazole gel 0.75% (NDCs, 00713-0637-37, 51672-4116-06 only)	FINACEA FOAM (azelaic acid) ivermectin metronidazole gel (all other NDCs) metronidazole lotion METROGEL (metronidazole) RHOFADÉ (oxymetazoline) ROSADAN (metronidazole)	<p><b>Subclass criteria:</b> Non-preferred agents are available only on appeal and require evidence of 30-day trials of all chemically unique preferred agents in the subclass.</p>
<b>ALZHEIMER'S AGENTS<sup>AP</sup></b>		
<p><b>CLASS PA CRITERIA:</b> Non-preferred agents require a 30-day trial of a preferred agent in the same subclass before they will be approved, unless one of the exceptions on the PA form is present.</p> <p>Prior authorization is required for members up to 45 years of age if there is no diagnosis of Alzheimer's disease.</p>		
<b>CHOLINESTERASE INHIBITORS</b>		
donepezil 5 mg and 10 mg donepezil ODT EXELON PATCHES (rivastigmine) galantamine tablets galantamine ER capsules rivastigmine capsules	ADLARTY PATCHES (donepezil) ARICEPT (donepezil) donepezil 23 mg* galantamine solution rivastigmine patches ZUNVEYL (benzgalantamine gluconate)	<p>*Donepezil 23 mg tablets will be authorized if the following criteria are met:</p> <ol style="list-style-type: none"> <li>1. There is a diagnosis of moderate-to-severe Alzheimer's Disease; <b>AND</b></li> <li>2. There has been a trial of donepezil 10 mg daily for at least three months and donepezil 20 mg daily for an additional one month.</li> </ol>

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>NMDA RECEPTOR ANTAGONIST</b>		
memantine memantine ER	memantine solution NAMENDA (memantine) solution, titration pak	
<b>CHOLINESTERASE INHIBITOR/NMDA RECEPTOR ANTAGONIST COMBINATIONS</b>		
	NAMZARIC (donepezil/memantine)	Combination agents require 30-day trials of each corresponding preferred single agent.
<b>ANALGESICS, NARCOTIC LONG-ACTING (Non-parenteral)<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require six-day trials of three chemically-distinct preferred agents (excluding fentanyl) <b>AND</b> a six-day trial of the generic form of the requested non-preferred agent (if available) before they will be approved, unless one of the exceptions on the PA form is present. If no generic form is available for the requested non-preferred brand agent, then another generic non-preferred agent must be trialed instead. <b>NOTE: All long-acting opioid agents require prior authorization for children under 18 years of age.</b> Requests must be for a Food and Drug Administration (FDA) approved age and indication and specify previous opioid and non-opioid therapies attempted.		
BUTRANS (buprenorphine) fentanyl transdermal 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, and 100 mcg/hr <sup>CL/PA</sup> morphine ER tablets tramadol ER tablets (generic ULTRAM ER)	ARYMO ER (morphine sulfate) BELBUCA (buprenorphine buccal film)* buprenorphine buccal film buprenorphine patches (all labelers including 00093) CONZIP ER (tramadol) fentanyl transdermal 37.6 mcg/hr, 62.5 mcg/hr and 87.5 mcg/hr hydrocodone ER capsules and tablets hydromorphone ER HYSINGLA ER (hydrocodone) KADIAN (morphine) methadone** MORPHABOND ER (morphine sulfate) morphine ER capsules (generic AVINZA) morphine ER capsules (generic KADIAN) MS CONTIN (morphine) oxycodone ER OXYCONTIN (oxycodone) oxymorphone ER tramadol ER (generic CONZIP ER)*** ULTRAM ER (tramadol) ZOHYDRO ER (hydrocodone)	*Belbuca prior authorization requires manual review. Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.  **Methadone will be authorized without a trial of the preferred agents if a diagnosis of cancer is submitted.  ***Tramadol ER (generic ConZip) requires a manual review and may be authorized for 90 days with submission of a detailed treatment plan including anticipated duration of treatment and scheduled follow-ups with the prescriber.
<b>ANALGESICS, NARCOTIC SHORT-ACTING (Non-parenteral)<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require six-day trials of at least four chemically-distinct preferred agents (based on the narcotic ingredient only), including the generic formulation of the requested non-preferred agent, before they will be approved, unless one of the exceptions on the PA form is present. <b>NOTE: All tramadol and codeine products require a prior authorization for children under 18 years of age.</b> Requests must be for an FDA approved age and indication and specify non-opioid therapies attempted.		
APAP/codeine butalbital/APAP/caffeine/codeine 50-325-30 mg	ABSTRAL (fentanyl) ACTIQ (fentanyl)	Fentanyl buccal, nasal, and sublingual products will only be authorized for a diagnosis of cancer and as an

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
codeine hydrocodone/APAP 2.5/325 mg, 5/325 mg, 7.5/325 mg, and 10/325 mg hydrocodone/APAP solution hydromorphone tablets meperidine oral solution morphine NUCYNТА (tapentadol) oxycodone capsules, solution, tablets oxycodone/APAP oxycodone/ASA tramadol tablets tramadol/APAP	butalbital/APAP/caffeine/codeine 50-300-30 mg butalbital/ASA/caffeine/codeine butorphanol DEMEROL (meperidine) dihydrocodeine/APAP/caffeine DILAUDID (hydromorphone) fentanyl FENTORA (fentanyl) FIORICET W/ CODEINE (butalbital/APAP/caffeine/codeine) FIORINAL W/ CODEINE (butalbital/ASA/caffeine/codeine) hydrocodone/APAP 5/300 mg, 7.5/300 mg and 10/300 mg hydrocodone/ibuprofen hydromorphone liquid, suppositories levorphanol LORCET (hydrocodone/APAP) LORTAB (hydrocodone/APAP) LORTAB SOLUTION (hydrocodone/acetaminophen) meperidine tablets morphine rectal suppository NORCO (hydrocodone/APAP) oxycodone concentrate oxycodone/ibuprofen oxymorphone pentazocine/naloxone PERCOCET (oxycodone/APAP) QDOLO SOLUTION (tramadol) ROXICODONE (oxycodone) ROXYBOND (oxycodone) SEGLENTIS (celecoxib/tramadol)* tramadol solution ULTRACET (tramadol/APAP) VICOPROFEN (hydrocodone/ibuprofen)	adjunct to a long-acting agent. These dosage forms will not be authorized for monotherapy.  <b>Limits:</b> Unless the patient has escalating cancer pain or another diagnosis supporting increased quantities of short-acting opioids, all short-acting solid forms of the narcotic analgesics are limited to 120 tablets per 30days. Longer-acting medications should be maximized to prevent unnecessary breakthrough pain in chronic pain therapy.  Immediate release tramadol is limited to 240 tablets per 30 days.  *Seglentis requires medical reasoning beyond convenience or enhanced compliance as to why the clinical need cannot be met with a preferred agent or combination of preferred single ingredient agents.
<b>ANALGESICS, NON-NARCOTIC SHORT ACTING</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 30-day trial of a preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
<b>SODIUM CHANNEL BLOCKER (Nav 1.8)</b>		
JOURNAVX (suzetrigine)		
<b>ANDROGENIC AGENTS</b>		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>CLASS PA CRITERIA:</b> A non-preferred agent will only be authorized if one of the exceptions on the PA form is present.		
ANDROGEL PUMP (testosterone) <sup>CL/PA*</sup> TESTIM (testosterone) testosterone cypionate vial <sup>CL/PA*</sup> testosterone enanthate vial <sup>CL/PA*</sup> testosterone gel 1.62%	ANDROGEL PACKETS (testosterone) ANDROID (methyltestosterone) AVEED (testosterone undecanoate) AZMIRO INJECTION (testosterone cypionate) FORTESTA (testosterone) JATENZO (testosterone undecanoate) METHITEST (methyltestosterone) methyltestosterone capsules NATESTO (testosterone) testosterone gel testosterone solution pump TESTRED (methyltestosterone) TLANDO (testosterone undecanoate) <b>UNDECATREX (testosterone undecanoate)</b> VOGELXO (testosterone) XYOSTED (testosterone enanthate)	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>ANESTHETICS, TOPICAL<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 10-day trials of each preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
lidocaine lidocaine/prilocaine xylocaine	lidocaine/hydrocortisone LIDOTRAL CREAM (lidocaine) LIDOZION LOTION (lidocaine) SYNERA (lidocaine/tetracaine)	
<b>ANGIOTENSIN MODULATORS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 14-day trials of each preferred agent in the same subclass, with the exception of the Direct Renin Inhibitors, before they will be approved, unless one of the exceptions on the PA form is present.		
<b>ACE INHIBITORS</b>		
benazepril captopril enalapril fosinopril lisinopril ramipril trandolapril	ACCUPRIL (quinapril) ALTACE (ramipril) enalapril solution EPANED SOLUTION (enalapril)* LOTENSIN (benazepril) moexipril perindopril PRINIVIL (lisinopril) QBRELIS SOLUTION (lisinopril)** <b>quinapril</b> ZESTRIL (lisinopril)	*Epaned solution (enalapril solution) will be authorized with a diagnosis of hypertension, symptomatic heart failure or asymptomatic left ventricular dysfunction provided that the patient is less than (<) seven years of age <b>OR</b> is unable to ingest a solid dosage form due to documented oral-motor difficulties or dysphagia.  **Qbrelis solution may be authorized for children six to 10 years of age who are unable to tolerate a solid dosage form. Qbrelis may also be authorized for older patients with clinical documentation indicating oral-motor difficulties or dysphagia.
<b>ACE INHIBITOR COMBINATION DRUGS</b>		
benazepril/amlodipine	ACCURETIC (quinapril/HCTZ)	



THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
benazepril/HCTZ captopril/HCTZ enalapril/HCTZ fosinopril/HCTZ lisinopril/HCTZ	LOTENSIN HCT (benazepril/HCTZ) LOTREL (benazepril/amlodipine) TARKA (trandolapril/verapamil) trandolapril/verapamil quinapril/HCTZ ZESTORETIC (lisinopril/HCTZ)	
<b>ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs)</b>		
irbesartan losartan olmesartan telmisartan valsartan	ATACAND (candesartan) AVAPRO (irbesartan) BENICAR (olmesartan) candesartan COZAAR (losartan) DIOVAN (valsartan) EDARBI (azilsartan) MICARDIS (telmisartan)	
<b>ARB COMBINATIONS</b>		
irbesartan/HCTZ losartan/HCTZ olmesartan/amlodipine olmesartan/amlodipine/HCTZ olmesartan/HCTZ valsartan/amlodipine valsartan/HCTZ	ATACAND-HCT (candesartan/HCTZ) AVALIDE (irbesartan/HCTZ) AZOR (olmesartan/amlodipine) BENICAR-HCT (olmesartan/HCTZ) candesartan/HCTZ DIOVAN-HCT (valsartan/HCTZ) EDARBYCLOR (azilsartan/chlorthalidone) EXFORGE (valsartan/amlodipine) EXFORGE HCT (valsartan/amlodipine/HCTZ) HYZAAR (losartan/HCTZ) MICARDIS-HCT (telmisartan/HCTZ) telmisartan/amlodipine telmisartan/HCTZ TRIBENZOR (olmesartan/amlodipine/HCTZ) valsartan/amlodipine/HCTZ	
<b>DIRECT RENIN INHIBITORS</b>		
	aliskiren TEKTURNA (aliskiren) TEKTURNA HCT (aliskiren/HCTZ)	<b>Substitute for Class Criteria:</b> Tekturna requires a 30-day trial of one preferred ACE, ARB, or combination agent, at the maximum tolerable dose, before it will be authorized unless one of the exceptions on the PA form is present.
<b>ANTIANGINAL &amp; ANTI-ISCHEMIC</b>		
<b>CLASS PA CRITERIA:</b> Agents in this class may only be authorized for patients with angina who are also taking a calcium channel blocker, a beta blocker, or a nitrite as single agents or a combination agent containing one of these ingredients.		
ranolazine <sup>AP</sup>	ASPRUZYO SPRINKLE ER (ranolazine) RANEXA	

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>ANTIBIOTICS, GI &amp; RELATED AGENTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 14-day trial of a preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
metronidazole tablets neomycin tinidazole VANCOCIN (vancomycin) vancomycin capsules	AEMCOLO TABLETS (rifamycin) DIFICID (fidaxomicin)* FIRVANQ SOLUTION (vancomycin)*** FLAGYL (metronidazole) LIKMEZ (metronidazole)** metronidazole capsules paromomycin vancomycin solution*** VOWST CAPSULES (fecal microbiota spores)*	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.  **Likmez may be authorized for those who are unable to ingest solid dosage forms of metronidazole due to documented oral-motor difficulties or dysphagia.  ***Vancomycin solution and Firvanq solution may be authorized for children up to nine years of age who are unable to ingest solid dosage forms of vancomycin. Therapy may be authorized for older patients with clinical documentation indicating oral-motor difficulties or dysphagia.
<b>ANTIBIOTICS, INHALED</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 28-day trial of a preferred agent and documentation of therapeutic failure before they will be approved, unless one of the exceptions on the PA form is present.		
BETHKIS (tobramycin) 300 mg/4 ml tobramycin 300 mg/5 ml (generic TOBI) tobramycin 300 mg/5 ml (generic KITABIS)	CAYSTON (aztreonam) KITABIS PAK (tobramycin) 300mg/5ml TOBI (tobramycin) TOBI PODHALER (tobramycin)	
<b>ANTIBIOTICS, TOPICAL</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 10-day trials of at least one preferred agent, including the generic formulation of the requested non-preferred agent, before they will be approved, unless one of the exceptions on the PA form is present.		
bacitracin (Rx, OTC) gentamicin sulfate mupirocin ointment	CENTANY (mupirocin) CORTISPORIN (bacitracin/neomycin/polymyxin/HC) mupirocin cream neomycin/polymyxin/pramoxine XEPI CREAM (ozenoxacin)	
<b>ANTIBIOTICS, VAGINAL</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require trials of each chemically-unique preferred agent at the manufacturer's recommended duration, before they will be approved, unless one of the exceptions on the PA form is present.		
CLEOCIN OVULE (clindamycin) CLEOCIN CREAM (clindamycin) metronidazole gel	clindamycin cream CLINDESSE (clindamycin) NUVESSA (metronidazole) SOLOSEC (secnidazole)	

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	VANDAZOLE (metronidazole) XACIATO GEL (clindamycin)	
<b>ANTICOAGULANTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a trial of each preferred agent in the same subclass, unless one of the exceptions on the PA form is present.		
<b>INJECTABLE<sup>CL/PA</sup></b>		
enoxaparin	ARIXTRA (fondaparinux) fondaparinux FRAGMIN (dalteparin) LOVENOX (enoxaparin)	
<b>ORAL</b>		
dabigatran ELIQUIS (apixaban) warfarin XARELTO TABLETS (rivaroxaban)*	PRADAXA (dabigatran) PRADAXA ORAL PELLETS (dabigatran etexilate) SAVAYSA (edoxaban) XARELTO SUSPENSION (rivaroxaban)	*Xarelto 2.5 mg tablets may be approved for a diagnosis of chronic coronary artery disease (CAD) or peripheral artery disease (PAD) AND is being used concurrently with aspirin.
<b>ANTICONSULSANTS</b>		
<b>CLASS PA CRITERIA:</b> For a diagnosis of seizure disorder, non-preferred agents require a 14-day trial of a preferred agent in the same subclass before they will be approved, unless one of the exceptions on the PA form is present; patients currently on established therapies shall be grandfathered.		
For all other diagnoses, non-preferred agents require a 30-day trial of a preferred agent in the same subclass before they will be approved, unless one of the exceptions on the PA form is present.		
In situations where AB-rated generic equivalent products are available, "Brand Medically Necessary" must be hand-written by the prescriber on the prescription for the brand name product to be reimbursed.		
<b>ADJUVANTS</b>		
BRIVIACT (brivaracetam) carbamazepine carbamazepine ER CARBATROL (carbamazepine) DEPAKOTE SPRINKLE CAPSULES (divalproex) divalproex divalproex ER divalproex sprinkle capsules EPITOL (carbamazepine) lacosamide solution, tablets LAMICTAL (lamotrigine) LAMICTAL CHEWABLE TABLETS (lamotrigine) LAMICTAL XR (lamotrigine)	APTiom (eslicarbazepine) BANZEL (rufinamide) carbamazepine oral suspension DEPAKOTE (divalproex) DEPAKOTE DR (divalproex) DEPAKOTE ER (divalproex) DIACOMIT CAPSULES/POWDER PACK (stiripentol)** ELEPSIA XR (levetiracetam) EPRONTIA SOLUTION (topiramate)**** EQUETRO (carbamazepine) felbamate FELBATOL (felbamate) FINTEPLA SOLUTION (fenfluramine)***** FYCOMPA (perampanel) KEPPRA (levetiracetam)	*Topiramate ER will be authorized after a 30-day trial of topiramate IR.  **Diacomit may only be approved as adjunctive therapy for a diagnosis of Dravet Syndrome when prescribed by, or in consultation with a neurologist <b>AND</b> requires a 30-day trial of valproate and clobazam unless one of the exceptions on the PA form is present. Diacomit must be used concurrently with clobazam.  ***Trokendi XR is available only on appeal.  ****Eprontia requires medical reasoning beyond convenience or enhanced compliance as to why the

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
lamotrigine lamotrigine ODT levetiracetam IR levetiracetam ER levetiracetam IR suspension oxcarbazepine tablets QUDEXY XR (topiramate ER) TEGRETOL SUSPENSION (carbamazepine) TEGRETOL XR (carbamazepine) topiramate IR tablets topiramate ER* topiramate IR sprinkle capsules topiramate ER sprinkle capsules (generic QUDEXY) TRILEPTAL SUSPENSION (oxcarbazepine) valproic acid zonisamide	KEPBRA SOLUTION (levetiracetam) KEPBRA XR (levetiracetam) LAMICTAL ODT (lamotrigine) lamotrigine dose pack lamotrigine ER MOTPOLY XR (lacosamide)***** oxcarbazepine suspension OXTELLAR XR (oxcarbazepine) rufinamide oral suspension, tablets SABRIL (vigabatrin) SPRITAM (levetiracetam) TEGRETOL TABLETS (carbamazepine) tiagabine TOPAMAX SPRINKLE CAPSULES (topiramate) TOPAMAX TABLETS (topiramate) TRILEPTAL TABLETS (oxcarbazepine) TROKENDI XR (topiramate)*** vigabatrin tablet/powder pack VIGAFYDE (vigabatrin solution) VIMPAT SOLUTION, TABLETS (lacosamide) XCOPRI (cenobamate) ZONISADE SOLUTION (zonisamide)***** <b>ZTALMY (ganaxolone)</b>	medical need cannot be met by using the preferred Topamax (topiramate) sprinkle/capsules.  *****Full PA criteria for Fintepla may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.  *****Zonisade may only be authorized for those who are unable to ingest solid dosage forms due to documented oral-motor difficulties or dysphagia <b>AND</b> have had a 14-day trial with a preferred agent available in a non-solid dosage form resulting in an inadequate treatment response.  *****Motpoly XR capsules may be authorized after a medical reason beyond convenience or enhanced compliance, as to why the clinical need cannot be met by using a preferred lacosamide agent, is provided.
<b>BARBITURATES<sup>AP</sup></b>		
phenobarbital primidone	MYSOLINE (primidone)	
<b>BENZODIAZEPINES<sup>AP</sup></b>		
clonazepam diazepam rectal gel diazepam tablets NAYZILAM NASAL SPRAY (midazolam) VALTOCO NASAL SPRAY (diazepam)	clobazam* clonazepam ODT KLONOPIN (clonazepam) LIBERVANT BUCCAL FILM (diazepam)** ONFI (clobazam)* ONFI SUSPENSION (clobazam)* SYMPAZAN (clobazam film)*	*Clobazam will be authorized as adjunctive therapy with any chronic anti-seizure medication, with the exception of other benzodiazepines. <b>NOTE:</b> Generic clobazam is preferred over brand Onfi.  **Libervant requires review by the Medical Director and is available only on appeal.
<b>CANNABINOIDS</b>		
EPIDIOLEX SOLUTION (cannabidiol) <sup>AP*</sup>		*Epidiolex may be authorized after 14-day trials of two of the following agents within the past 12 months: clobazam, levetiracetam, valproate, lamotrigine, topiramate, rufinamide or felbamate.
<b>HYDANTOINS<sup>AP</sup></b>		
DILANTIN CAPSULES, CHEWABLE TABLETS, SUSPENSION (phenytoin sodium)	PHENYTEK (phenytoin)	

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
extended) PEGANONE (ethotoin) phenytoin capsules, chewable tablets, suspension		
<b>SUCCINIMIDES</b>		
CELONTIN (methsuximide) ethosuximide capsules ethosuximide syrup	ZARONTIN CAPSULES (ethosuximide) ZARONTIN SYRUP (ethosuximide) methsuximide	
<b>ANTIDEPRESSANTS, OTHER</b>		
<b>CLASS PA CRITERIA:</b> See below for individual subclass criteria.		
<b>MONOAMINE OXIDASE INHIBITORS (MAOIs)<sup>AP</sup></b>		
	MARPLAN (isocarboxazid) NARDIL (phenelzine) phenelzine tranylcypromine	Patients stabilized on MAOI agents will be grandfathered.
<b>SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs)<sup>AP</sup></b>		
desvenlafaxine succinate ER (generic PRISTIQ) duloxetine capsules venlafaxine ER capsules venlafaxine ER tablets venlafaxine IR tablets	CYMBALTA (duloxetine) desvenlafaxine fumarate ER EFFEXOR XR (venlafaxine) FETZIMA (levomilnacipran) PRISTIQ (desvenlafaxine)	Non-preferred agents require separate 30-day trials of a preferred agent in this subclass <b>AND</b> a Selective Serotonin Reuptake Inhibitors (SSRI) before they will be approved, unless one of the exceptions on the PA form is present.
<b>SECOND GENERATION NON-SSRI, OTHER<sup>AP</sup></b>		
bupropion IR bupropion SR bupropion XL mirtazapine trazodone	AUVELITY (dextromethorphan HBr/bupropion)* EMSAM (selegiline) FORFIVO XL (bupropion) Nefazodone RALDESY SOLUTION (trazodone)** REMERON (mirtazapine) TRINTELLIX (vortioxetine) VIIBRYD (vilazodone HCl) vilazodone WELLBUTRIN SR (bupropion)	Non-preferred agents require separate 30-day trials of a preferred agent in this subclass <b>AND</b> an SSRI before they will be approved, unless one of the exceptions on the PA form is present.  *Auvelity may be approved after the following has been met: <ol style="list-style-type: none"> <li>1. The diagnosis is Major depressive disorder; <b>AND</b></li> <li>2. Documentation is provided giving medical reasoning beyond convenience as to why the clinical need cannot be met with using a combination of the preferred individual components; <b>AND</b></li> <li>3. A trial of 60 days resulting in an inadequate clinical response, with two distinct classes used to treat major depressive disorder, with one of the trials being bupropion.</li> </ol>

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		**Raldesy may only be authorized for those who are unable to ingest solid dosage forms of trazodone due to documented oral-motor difficulties or dysphagia.
<b>SELECTED TRICYCLIC ANTIDEPRESSANTS (TCAs)</b>		
imipramine HCl	imipramine pamoate	Non-preferred agents require a 12-week trial of imipramine HCl before they will be approved, unless one of the exceptions on the PA form is present.
<b>ANTIDEPRESSANTS, SSRIs<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 30-day trials of at least two preferred agents before they will be approved, unless one of the exceptions on the PA form is present.		
Upon hospital discharge, patients admitted with a primary mental health diagnosis who have been stabilized on a non-preferred SSRI will receive an authorization to continue that drug.		
citalopram escitalopram tablets fluoxetine capsules, solution fluvoxamine paroxetine sertraline	CELEXA (citalopram) citalopram capsules escitalopram solution fluoxetine tablets fluoxetine DR capsules fluvoxamine ER LEXAPRO (escitalopram) paroxetine 7.5 mg capsules paroxetine ER paroxetine suspension PAXIL (paroxetine) PAXIL CR (paroxetine) PEXEVA (paroxetine) PROZAC (fluoxetine) SARAFEM (fluoxetine) sertraline capsules ZOLOFT (sertraline)	
<b>ANTIEMETICS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> See below for subclass criteria.		
<b>5HT3 RECEPTOR BLOCKERS</b>		
granisetron tablets ondansetron ODT, solution, tablets	ondansetron vials SANCUSO (granisetron) SUSTOL (granisetron) ZOFTRAN (ondansetron) ZUPLENZ (ondansetron)	Non-preferred agents require a three-day trial of a preferred agent before they will be approved, unless one of the exceptions on the PA form is present.
<b>CANNABINOIDS</b>		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	dronabinol* MARINOL (dronabinol)*	*Dronabinol will only be authorized for: 1. The treatment of anorexia associated with weight loss in patients with AIDS or cancer and unresponsive to megestrol; <b>OR</b> 2. The prophylaxis of chemotherapy induced nausea and vomiting unresponsive to three-day trials of ondansetron or promethazine for patients who are 18 to 65 years of age.
<b>SUBSTANCE P ANTAGONISTS</b>		
aprepitant EMEND 125 mg CAPSULES (aprepitant) EMEND SUSPENSION (aprepitant)	EMEND 80 mg CAPSULES, DOSEPAK (aprepitant) VARUBI (rolapitant)	Non-preferred agents require a three-day trial of a preferred agent before they will be approved, unless one of the exceptions on the PA form is present.
<b>COMBINATIONS</b>		
DICLEGIS (doxylamine/pyridoxine) doxylamine/pyridoxine (generic DICLEGIS)	AKYNZEO (netupitant/palonosetron) BONJESTA (doxylamine/pyridoxine)	Non-preferred agents may only be approved after a trial and failure of a preferred agent unless one of the exceptions on the PA form is present.
<b>ANTIFUNGALS, ORAL</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents will only be authorized if one of the exceptions on the PA form is present.		
clotrimazole fluconazole* griseofulvin*** nystatin terbinafine <sup>CL/PA</sup>	CRESEMBA (isavuconazonium ) <sup>CL/PA**</sup> BREXAFEMME (ibrexafungerp) DIFLUCAN (fluconazole) flucytosine itraconazole ketoconazole**** MYCELEX (clotrimazole) NOXAFIL (posaconazole) ORAVIG (miconazole) posaconazole tablets SPORANOX (itraconazole) TOLSURA (itraconazole) VFEND (voriconazole) VIVJOA (oteseconazole) voriconazole suspension voriconazole tablets	*PA is required when limits are exceeded.  **Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.  ***PA is not required for griseofulvin suspension for children up to 18 years of age for the treatment of tinea capitis.  ****Ketoconazole will be authorized if the following criteria are met: 1. Diagnosis of one of the following fungal infections: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, or paracoccidioidomycosis; <b>AND</b> 2. Documented failure or intolerance of all other diagnosis-appropriate antifungal therapies, i.e., itraconazole, fluconazole, flucytosine, etc.; <b>AND</b> 3. Baseline assessment of the liver status including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, alkaline phosphatase, prothrombin

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		<p>time, and international normalized ratio (INR) before starting treatment; <b>AND</b></p> <p>4. Weekly monitoring of serum ALT for the duration of treatment (if ALT values increase to a level above the upper limit of normal or 30% above baseline, or if the patient develops symptoms of abnormal liver function, treatment should be interrupted, and a full set of liver tests be obtained. Liver tests should be repeated to ensure normalization of values); <b>AND</b></p> <p>5. Assessment of all concomitant medications for potential adverse drug interactions with ketoconazole.</p> <p><b>Ketoconazole will not be authorized for treatment for fungal infections of the skin and nails.</b></p>
<b>ANTIFUNGALS, TOPICAL<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 14-day trials of two preferred agents before they will be approved, unless one of the exceptions on the PA form is present. If a non-preferred shampoo is requested, a 14-day trial of one preferred product (i.e., ketoconazole shampoo) is required.		
<b>ANTIFUNGALS</b>		
econazole ketoconazole cream, shampoo miconazole (OTC) nystatin	CICLODAN (ciclopirox) ciclopirox EXTINA (ketoconazole) GYNAZOLE 1 CREAM (butoconazole) KERYDIN (tavaborole) ketoconazole foam KETODAN (ketoconazole) luliconazole cream miconazole/petrolatum/zinc oxide naftifine cream NAFTIN GEL (naftifine) oxiconazole cream OXISTAT (oxiconazole)** sulconazole nitrate cream, solution tavaborole 5% topical solution VUSION (miconazole/petrolatum/zinc oxide)	<p>*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.</p> <p>**Oxistat cream will be authorized for children up to 13 years of age for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor.</p>
<b>ANTIFUNGAL/STEROID COMBINATIONS</b>		
clotrimazole/betamethasone cream	clotrimazole/betamethasone lotion nystatin/triamcinolone	
<b>ANTIHEMOPHILIA FACTOR AGENTS<sup>CL/PA</sup></b>		



THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>CLASS PA CRITERIA:</b> All agents will require prior authorization, and non-preferred agents require medical reasoning explaining why the need cannot be met using a preferred product.		
All currently established regimens shall be grandfathered with documentation of adherence to therapy.		
<b>FACTOR VIII</b>		
AFSTYLA ALPHANATE HEMOFIL M HUMATE-P JIVI KOATE KOGENATE FS KOVALTRY NOVOEIGHT NUWIQ WILATE XYNTHA XYNTHA SOLOFUSE	ADVATE ADYNOVATE ALTUVIIIO ELOCTATE ESPEROCT RECOMBINATE VONVENDI	
<b>BYPASSING AGENTS</b>		
	FEIBA NOVOSEVEN SEVENFACT	
<b>FACTOR IX</b>		
ALPHANINE SD ALPROLIX BENEFIX IXINITY MONONINE PROFILNINE RIXUBIS	IDELVION REBINYN	
<b>NON-FACTOR REPLACEMENT</b>		
HEMLIBRA (emicizumab-kxwh)	ALHEMO (concizumab-mtci)* HYMPAVZI (marstacimab-hncq) QFITLIA (fitusiran)	*Alhemo may be approvable for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients greater than or equal to (≥) 12 years of age with hemophilia B (congenital factor IX deficiency) with factor IX inhibitors.
<b>ANTIHYPERTENSIVES, SYMPATHOLYTICS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 30-day trials of each preferred unique chemical entity in the corresponding formulation before they will be approved, unless one of the exceptions on the PA form is present.		
clonidine patch clonidine tablets		
<b>ANTIHYPERURICEMICS</b>		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 30-day trial of one of the preferred agents for the prevention of gouty arthritis attacks (colchicine/probenecid, probenecid, or allopurinol) before they will be approved, unless one of the exceptions on the PA form is present.		
<b>ANTIMITOTICS</b>		
colchicine tablets	colchicine capsules COLCRYS TABLETS (colchicine) MITIGARE (colchicine) GLOPERBA (colchicine)*	In the case of acute gouty attacks, a 10-day supply (20 units) of the preferred agent(s) in this subclass will be authorized per 90 days.  *Gloperba may only be authorized for those who are unable to ingest solid dosage forms due to documented oral-motor difficulties or dysphagia.
<b>ANTIMITOTIC-URICOSURIC COMBINATION</b>		
colchicine/probenecid		
<b>URICOSURIC</b>		
probenecid		
<b>XANTHINE OXIDASE INHIBITORS</b>		
allopurinol febuxostat tablets	ULORIC (febuxostat) ZYLOPRIM (allopurinol)	
<b>ANTIMIGRAINE AGENTS, PROPHYLAXIS<sup>CL/PA</sup></b>		
<b>CLASS PA CRITERIA:</b> All agents require a prior authorization. Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink. Non-preferred agents require a 90-day trial of all preferred agents.		
AIMOVI (erenumab) AJOVY (fremanezumab) EMGALITY AUTO-INJECTOR, 120 mg SYRINGES (galcanezumab)	EMGALITY 300 mg SYRINGES (galcanezumab)* NURTEC ODT (rimegepant)** QULIPTA (atogepant)	*Emgality 300 mg/3 mL requires review by the Medical Director and is available only on appeal.  **Nurtec ODT for a diagnosis of <b>Migraine Prophylaxis</b> : Maximum Quantity limit of 16 tablets per 32 days.
<b>ANTIMIGRAINE AGENTS, ACUTE<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require three-day trials of each preferred unique chemical entity as well as a three-day trial using the same route of administration as the requested agent (if available), before they will be approved, unless one of the exceptions on the PA form is present.		
<b>TRIPTANS</b>		
IMITREX NASAL SPRAY (sumatriptan) naratriptan rizatriptan ODT rizatriptan tablet sumatriptan injection pens, vials sumatriptan nasal spray sumatriptan tablets zolmitriptan tablets zolmitriptan ODT	almotriptan AMERGE (naratriptan) eletriptan FROVA (frovatriptan) frovatriptan MAXALT (rizatriptan) MAXALT MLT (rizatriptan) ONZETRA XSAIL (sumatriptan)* RELPA (eletriptan)	*In addition to the Class Criteria: Onzetra Xsail and Tosymra require three-day trials of each preferred oral, nasal, and injectable forms of sumatriptan.

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	sumatriptan cartridges TOSYMRA NASAL SPRAY (sumatriptan)* ZEMBRACE SYMTOUCH (sumatriptan) zolmitriptan nasal spray ZOMIG (zolmitriptan) ZOMIG ZMT (zolmitriptan)	
TRIPTAN COMBINATIONS		
	sumatriptan/naproxen sodium SYMBRAVO (meloxicam/rizatriptan)* TREXIMET (sumatriptan/naproxen sodium)	*Symbravo may be approved after the following has been met: <ol style="list-style-type: none"> <li>1. Symbravo is being used in adult patients for acute treatment of migraine with or without aura; <b>AND</b></li> <li>2. A trial resulting in an inadequate clinical response with sumatriptan/naproxen sodium; <b>AND</b></li> <li>3. A trial resulting in an inadequate clinical response with a preferred oral CGRP for migraine treatment; <b>AND</b></li> <li>4. Documentation is provided giving medical reasoning beyond convenience as to why the clinical need cannot be met with using a combination of the preferred individual components.</li> </ol>
NURTEC ODT (rimegepant)* UBRELVY (ubrogepant)***	CAMBIA (diclofenac) D.H.E 45 AMPULE (dihydroergotamine)** dihydroergotamine injection, nasal spray** ELYXYB (celecoxib) MIGERGOT RECTAL SUPPOSITORY (ergotamine/caffeine)** REYVOW (lasmiditan)*** TRUDHESA SPRAY (dihydroergotamine)** ZAVZPRET NASAL SPRAY (zavegepant)****	*Nurtec Orally Disintegrating Tablet (ODT) For a diagnosis of <b>Migraine Treatment</b> : requires three-day trials of two preferred chemically distinct triptans before it may be approved, unless one of the exceptions on the PA form is present. Maximum Quantity limit of eight tablets per 30 days.  **All non-preferred Ergot Alkaloid agents require three-day trials of two preferred triptans as well as a three-day trial of a preferred triptan using the same route of administration as the requested agent (if available), before they will be approved, unless one of the exceptions on the PA form is present. <b>NOTE: Ergot derivatives should not be used with or within 24 hours of triptans.</b>  <b>**Additional Ergot Alkaloid criteria:</b> <b>Nasal spray:</b>

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		<p>Dihydroergotamine nasal spray and Trudhesa spray may only be authorized after a trial and failure of Migranal spray.</p> <p><b><u>Rectal suppository:</u></b> Migergot rectal suppository may only be authorized after a trial and failure of a preferred triptan nasal spray.</p> <p><b><u>Injection:</u></b> Dihydroergotamine injection and D.H.E 45 ampule may only be approved for cluster headaches.</p> <p>***Ubrelvy and Reyvow require three-day trials of two preferred chemically distinct triptans as well as a three-day trial of Nurtec ODT before they may be approved, unless one of the exceptions on the PA form is present.</p> <p>****Zavzpret may be authorized after a trial and failure of a preferred CGRP agent used for acute treatment <b>AND</b> a trial and failure of two chemically distinct preferred triptans, including sumatriptan nasal spray (unless contraindicated).</p>
<b>ANTIPARASITICS, TOPICAL<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require trials of each preferred agent (which are age and weight appropriate) before they will be approved, unless one of the exceptions on the PA form is present.		
NATROBA (spinosad) permethrin 5% cream pyrethrins-piperonyl butoxide (OTC) spinosad (NDC 52246057004)	ELIMITE CREAM (permethrin) EURAX (crotamiton) ivermectin 0.5% lotion LICE EGG REMOVER (benzalkonium chloride) (OTC) lindane malathion OVIDE (malathion) PRURADIK (crotamiton) SKLICE (ivermectin) spinosad (all other NDC's) VANALICE (piperonyl/pyrethrum)	
<b>ANTIPARKINSON'S AGENTS</b>		
<b>CLASS PA CRITERIA:</b> Patients starting therapy on drugs in this class must show a documented allergy to all preferred agents in the corresponding subclass before a non-preferred agent will be authorized.		
<b>ANTICHOLINERGICS</b>		
benztropine trihexyphenidyl		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>Catechol-O- Methyltransferase (COMT) INHIBITORS</b>		
entacapone	COMTAN (entacapone) ONGENTYS (opicapone) tolcapone	COMT Inhibitor agents will only be approved as add-on therapy to a levodopa-containing regimen for treatment of documented motor complications.
<b>DOPAMINE AGONISTS</b>		
APOKYN PEN (apomorphine) bromocriptine pramipexole ropinirole	apomorphine cartridge KYNMOBI FILM (apomorphine) MIRAPEX ER (pramipexole)* NEUPRO (rotigotine) pramipexole ER ropinirole ER	*Mirapex ER will be authorized for a diagnosis of Parkinsonism without a trial of preferred agents.
<b>OTHER ANTIPARKINSON'S AGENTS</b>		
amantadine <sup>AP*</sup> carbidopa/levodopa levodopa/carbidopa/entacapone selegiline	AZILECT (rasagiline) Carbidopa CREXONT (carbidopa/levodopa) GOCOVRI ER (amantadine) INBRIJA (levodopa) levodopa/carbidopa ODT NOURIANZ (istradefylline) OSMOLEX ER (amantadine) PARLODEL (bromocriptine) rasagiline RYTARY (levodopa/carbidopa) SINEMET (levodopa/carbidopa) STALEVO (levodopa/carbidopa/entacapone) XADAGO (safinamide) ZELAPAR (selegiline)	*Amantadine will not be authorized for the treatment or prophylaxis of influenza.
<b>ANTIPSORIATICS, TOPICAL</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 30-day trial of a preferred agent. Documentation describing the reason for failure of the preferred agent must be provided. The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
calcipotriene solution ENSTILAR (calcipotriene/betamethasone) TACLONEX SUSPENSION (calcipotriene/betamethasone)	calcipotriene cream calcipotriene/betamethasone ointment, suspension calcitriol SORILUX (calcipotriene) tazarotene cream VTAMA (tapinarof) ZORYVE 0.3% CREAM*, FOAM** (roflumilast)	<p>*Zoryve 0.3% cream or foam for <b>plaque psoriasis</b>: Requires a 30-day trial of either Taclonex suspension, Enstilar, OR calcipotriene solution.</p> <p>**Zoryve 0.3% foam for <b>seborrheic dermatitis</b>:</p> <ol style="list-style-type: none"> <li>Requires a <u>concurrent</u> trial with an antifungal shampoo (e.g., ketoconazole) AND a high potency corticosteroid (foam, lotion, shampoo or spray) for four weeks.</li> <li>For seborrheic dermatitis <b>NOT</b> affecting the scalp:               <ol style="list-style-type: none"> <li>A <u>concurrent</u> trial with a topical antifungal (e.g., ketoconazole cream) AND a high potency corticosteroid for two weeks AND</li> <li>A <u>concurrent</u> trial with a topical antifungal (e.g., ketoconazole cream) AND tacrolimus for four weeks.</li> </ol> </li> </ol>

## ANTIPSYCHOTICS, ATYPICAL AND COMBINATION

**CLASS PA CRITERIA:** All antipsychotic agents require prior authorization for children up to 18 years of age. All PA requests for antipsychotics for children six years of age and younger will be reviewed by Medicaid's consultant psychiatrist.

Non-preferred agents require 30-day trials of two preferred Atypical Antipsychotics approved or medically accepted for the member's diagnosis or indication, including the generic formulation of the requested agent (if available), before they will be approved unless one of the exceptions on the PA form is present. When determining requests for non-preferred products, any trial utilizing a preferred agent whose dose or duration was limited due to adverse effects or clear lack of efficacy will be considered complete only if the agent was being taken within the FDA approved therapeutic range.\*

Patients shall be grandfathered onto their existing therapy, provided the requested agent is being used according to the manufacturer label. Continuation of therapy for an off-label indication or non-standard dosage may be granted a 30-day prior authorization while the medical director reviews the request.

\*According to manufacturer dosing recommendations.

SINGLE INGREDIENT		
ABILIFY ASIMTUFI (aripiprazole) <sup>CL/PA</sup> ABILIFY MAINTENA (aripiprazole) <sup>CL/PA</sup> aripiprazole tablets ARISTADA (aripiprazole) <sup>CL/PA</sup> ARISTADA INITIO (aripiprazole) <sup>CL/PA</sup> asenapine sublingual tablets clozapine INVEGA HAFYERA (paliperidone) <sup>CL/PA*</sup> INVEGA SUSTENNA (paliperidone) <sup>CL/PA</sup> INVEGA TRINZA (paliperidone) <sup>CL/PA**</sup> lurasidone	ABILIFY MYCITE (aripiprazole) ABILIFY TABLETS (aripiprazole) ADASUVE (loxapine) aripiprazole ODT aripiprazole solution CAPLYTA (lumateperone) clozapine ODT CLOZARIL (clozapine) COBENFY (xanomeline/trospium) ERZOFRI (paliperidone) FANAPT (iloperidone)	<p><b>The following criteria exceptions apply to the specified products:</b></p> <p>*Invega Hafyera may only be authorized after four-month treatment with Invega Sustenna or at least a one three-month cycle with Invega Trinza.</p> <p>**Invega Trinza will be authorized after four-month treatment with Invega Sustenna</p> <p>***Quetiapine 25 mg will be authorized:</p>

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
olanzapine olanzapine ODT paliperidone ER PERSERIS (risperidone) <sup>CL/PA</sup> quetiapine <sup>AP</sup> for the 25 mg Tablet Only*** quetiapine ER risperidone ODT, solution, tablets <b>UZEDY (risperidone)</b> VRAYLAR (cariprazine)***** ziprasidone	GEODON (ziprasidone) GEODON IM (ziprasidone) INVEGA ER (paliperidone) LATUDA (lurasidone) LYBALVI (olanzapine/samidorphan)**** NUPLAZID (pimavanserin)***** olanzapine IM <sup>CL/PA</sup> olanzapine/fluoxetine OPIPZA FILM (aripiprazole) REXULTI (brexpiprazole) RISPERDAL (risperidone) RISPERDAL CONSTA (risperidone) <sup>CL/PA</sup> SAPHRIS (asenapine) SECUADO (asenapine) SEROQUEL (quetiapine) SEROQUEL XR (quetiapine) VERSACLOZ (clozapine) ZYPREXA (olanzapine) ZYPREXA IM (olanzapine) <sup>CL/PA</sup> ZYPREXA RELPREVV (olanzapine)	<ol style="list-style-type: none"> <li>For a diagnosis of schizophrenia; <b>OR</b></li> <li>For a diagnosis of bipolar disorder; <b>OR</b></li> <li>When prescribed concurrently with other strengths of Seroquel in order to achieve therapeutic treatment levels.</li> </ol> <p><b>Quetiapine 25 mg will not be authorized for use as a sedative hypnotic.</b></p> <p>****Patient must have had a positive response with olanzapine and experienced clinically significant weight gain (documentation must be provided) which necessitated disruption of treatment. Patient must also have had an intolerance, inadequate treatment response or contraindication to two preferred antipsychotics, which have a lower potential of weight gain, prior to Lybalvi approval. <b><i>Prior to initiating Lybalvi, there should be at least a seven-day opioid-free interval from the last use of short-acting opioids, and at least a 14-day opioid free interval from the last use of long-acting opioids to avoid precipitation of opioid withdrawal.</i></b></p> <p>*****Nuplazid may only be authorized for the treatment of Parkinson Disease Induced Psychosis after documented treatment failure with quetiapine.</p> <p>*****Vraylar may be authorized for the indication of major depressive disorder only after a 30-day trial and failure of two preferred antidepressants. For all other indications, a 30-day trial and failure of one preferred antipsychotic is required.</p>
<b>ANTIRETROVIRALS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred drugs require medical reasoning beyond convenience or enhanced compliance as to why the clinical need cannot be met with a preferred agent or combination of preferred agents. <b>NOTE:</b> Regimens consisting of preferred agents will result in no more than one additional unit per day over equivalent regimens composed of non-preferred agents. Patients already on a non-preferred regimen shall be grandfathered.		
<b>SINGLE TABLET REGIMENS</b>		
BIKTARVY (bictegravir/emtricitabine/tenofovir alafenamide) COMPLERA (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) DOVATO (dolutegravir/lamivudine)	ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumarate) efavirenz/lamivudine/tenofovir disoproxil fumarate JULUCA (dolutegravir/rilpivirine) SYMFI (efavirenz/lamivudine/tenofovir disoproxil fumarate) SYMFI LO (efavirenz/lamivudine/tenofovir	*Stribild requires medical reasoning beyond convenience or enhanced compliance as to why the medical need cannot be met with the preferred agent Genvoya.

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
efavirenz/emtricitabine/tenofovir disoproxil fumarate GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) ODEFSEY (emtricitabine/rilpivirine/tenofovir alafenamide) TRIUMEQ (abacavir/dolutegravir/lamivudine)	disoproxil fumarate) STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate)* SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) TRIUMEQ PD (abacavir/dolutegravir/lamivudine)	
<b>INTEGRASE STRAND TRANSFER INHIBITORS</b>		
ISENTRESS (raltegravir potassium) TIVICAY (dolutegravir sodium) TIVICAY PD (dolutegravir sodium)	ISENTRESS HD (raltegravir potassium)	
<b>NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI)</b>		
abacavir sulfate tablets EMTRIVA (emtricitabine) EPIVIR SOLUTION (lamivudine) lamivudine tenofovir disoproxil fumarate VIREAD ORAL POWDER (tenofovir disoproxil fumarate) ZIAGEN SOLUTION (abacavir sulfate) zidovudine	abacavir sulfate solution didanosine DR capsules emtricitabine capsules EPIVIR TABLETS (lamivudine) RETROVIR (zidovudine) stavudine VIDEX EC (didanosine) VIDEX SOLUTION (didanosine) VIREAD TABLETS (tenofovir disoproxil fumarate) ZIAGEN TABLETS (abacavir sulfate)	
<b>NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)</b>		
efavirenz	EDURANT (rilpivirine) EDURANT PED (rilpivirine) etravirine INTELENCE (etravirine) nevirapine nevirapine ER PIFELTRO (doravirine) SUSTIVA (efavirenz) VIRAMUNE ER 24H (nevirapine) VIRAMUNE SUSPENSION (nevirapine)	
<b>PHARMACOENHANCER – CYTOCHROME P450 INHIBITOR</b>		
TYBOST (cobicistat)		
<b>PROTEASE INHIBITORS (PEPTIDIC)</b>		
atazanavir EVOTAZ (atazanavir/cobicistat) REYATAZ POWDER PACK (atazanavir) ritonavir tablets	fosamprenavir LEXIVA (fosamprenavir) NORVIR (ritonavir) REYATAZ CAPSULES (atazanavir)	Norvir powder pack may be authorized for those who are unable to ingest solid dosage forms due to documented oral-motor difficulties or dysphagia.



THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	VIRACEPT (nelfinavir mesylate)	
	<b>PROTEASE INHIBITORS (NON-PEPTIDIC)</b>	
darunavir PREZCOBIX (darunavir/cobicistat)	APTIVUS (tipranavir) PREZISTA (darunavir)	
	<b>ENTRY INHIBITORS – CCR5 CO-RECEPTOR ANTAGONISTS</b>	
	maraviroc SELZENTRY (maraviroc)	
	<b>ENTRY INHIBITORS – FUSION INHIBITORS</b>	
	FUZEON (enfuvirtide)*	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
	<b>COMBINATION PRODUCTS – NRTIs</b>	
abacavir/lamivudine lamivudine/zidovudine	abacavir/lamivudine/zidovudine CIMDUO (lamivudine/tenofovir disoproxil fumarate) COMBIVIR (lamivudine/zidovudine) EPZICOM (abacavir/lamivudine) TEMIXYS (lamivudine/tenofovir disoproxil fumarate) TRIZIVIR (abacavir/lamivudine/zidovudine)	
	<b>COMBINATION PRODUCTS – NUCLEOSIDE &amp; NUCLEOTIDE ANALOG RTIs</b>	
DESCOVY (emtricitabine/tenofovir alafenamide) emtricitabine/tenofovir alafenamide	TRUVADA (emtricitabine/tenofovir alafenamide)	
	<b>COMBINATION PRODUCTS – PROTEASE INHIBITORS</b>	
lopinavir/ritonavir	KALETRA (lopinavir/ritonavir)	
	<b>PRODUCTS FOR PRE-EXPOSURE PROPHYLAXIS (PrEP)</b>	
APRETUDE (cabotegravir) DESCOVY (emtricitabine/tenofovir alafenamide) emtricitabine/tenofovir alafenamide YEZTUGO TABLETS, VIAL (lenacapavir)	TRUVADA (emtricitabine/tenofovir alafenamide)	
<b>ANTIVIRALS, ORAL</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require five-day trials of each preferred agent in the same subclass before they will be approved, unless one of the exceptions on the PA form is present.		
	<b>ANTI HERPES</b>	
acyclovir valacyclovir	famciclovir SITAVIG (acyclovir) VALTREX (valacyclovir)	

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>ANTI-INFLUENZA</b>		
oseltamivir <b>PAXLOVID (nirmatrelvir/ritonavir)</b>	FLUMADINE (rimantadine) RELENZA (zanamivir) rimantadine TAMIFLU (oseltamivir) XOFLUZA (baloxavir)	<b>In addition to the Class Criteria:</b> The anti-influenza agents will be authorized only for a diagnosis of influenza.
<b>ANTIVIRALS, TOPICAL<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a five-day trial of the preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
acyclovir ointment DENA VIR (penciclovir)	acyclovir cream <b>ANZUPGO (delgocitinib)</b> docosanol cream penciclovir cream	
<b>BETA BLOCKERS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 14-day trials of three chemically-distinct preferred agents, including the generic formulation of the requested non-preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
<b>BETA BLOCKERS</b>		
acebutolol atenolol betaxolol bisoprolol HEMANGEOL (propranolol)* metoprolol metoprolol ER nadolol nebivolol pindolol propranolol propranolol ER SORINE (sotalol) sotalol timolol	BETAPACE (sotalol) BYSTOLIC (nebivolol) CORCARD (nadolol) INDERAL LA (propranolol) INDERAL XL (propranolol) INNOPRAN XL (propranolol) KAPSPARGO SPRINKLE (metoprolol) <b>LOPRESSOR</b> tablets, <b>solution</b> (metoprolol) TENORMIN (atenolol) TOPROL XL (metoprolol)	*Hemangeol will be authorized for the treatment of proliferating infantile hemangioma requiring systemic therapy.
<b>BETA BLOCKER/DIURETIC COMBINATION DRUGS</b>		
atenolol/chlorthalidone bisoprolol/HCTZ metoprolol/HCTZ propranolol/HCTZ	nadolol/bendroflumethiazide TENORETIC (atenolol/chlorthalidone) ZIAC (bisoprolol/HCTZ)	
<b>BETA- AND ALPHA-BLOCKERS</b>		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
carvedilol labetalol	carvedilol ER capsules COREG (carvedilol) COREG CR (carvedilol)	
<b>BLADDER RELAXANT PREPARATIONS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 30-day trials of each chemically distinct preferred agent before they will be approved, unless one of the exceptions on the PA form is present		
DETROL LA (tolterodine) fesoterodine ER GELNIQUE (oxybutynin) MYRBETRIQ TABLETS (mirabegron) oxybutynin IR oxybutynin ER OXYTROL (oxybutynin) solifenacin	darifenacin ER tablets DETROL (tolterodine) DITROPAN XL (oxybutynin) ENABLEX (darifenacin) flavoxate GEMTESA (vibegron) mirabegron ER MYRBETRIQ SUSPENSION (mirabegron) tolterodine tolterodine ER TOVIAZ (fesoterodine) trospium trospium ER VESICARE (solifenacin) VESICARE LS (solifenacin)	
<b>BONE RESORPTION SUPPRESSION AND RELATED AGENTS</b>		
<b>CLASS PA CRITERIA:</b> See below for class criteria.		
<b>BISPHOSPHONATES</b>		
alendronate tablets ibandronate	ACTONEL (risedronate) alendronate solution ATELVIA (risedronate) BINOSTO (alendronate) BONIVA (ibandronate) FOSAMAX TABLETS (alendronate) FOSAMAX PLUS D (alendronate/vitamin D) risedronate	Non-preferred agents require six-month trials of <b>each</b> preferred Bisphosphonate agent before they will be approved, unless one of the exceptions on the PA form is present.
<b>OTHER BONE RESORPTION SUPPRESSION AND RELATED AGENTS</b>		
	BONSITY (teriparatide) calcitonin EVISTA (raloxifene)* FORTEO (teriparatide) MIACALCIN (calcitonin) raloxifene* teriparatide TYMLOS (abaloparatide)	Non-preferred agents require a six-month trial of a preferred Bisphosphonate agent before they will be approved, unless one of the exceptions on the PA form is present.  *Raloxifene will be authorized for postmenopausal women with osteoporosis who are at high risk for invasive breast cancer.

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>BPH TREATMENTS</b>		
<b>CLASS PA CRITERIA:</b> See below for individual subclass criteria.		
<b>5-ALPHA-REDUCTASE (5AR) INHIBITORS AND PDE-5 AGENTS</b>		
finasteride	AVODART (dutasteride) CIALIS 5 mg (tadalafil) dutasteride ENTADFI CAPSULES (finasteride/tadalafil)* PROSCAR (finasteride) tadalafil	Non-preferred 5AR agents require a 30-day trial of finasteride before they will be approved, unless one of the exceptions on the PA form is present.  Non-preferred PDE-5 agents require 30-day trials of finasteride <b>AND</b> a preferred alpha blocker before they will be approved, unless one of the exceptions on the PA form is present.  *Documentation of medical reasoning beyond convenience must be provided as to why the clinical need cannot be met with finasteride used in combination with tadalafil.
<b>ALPHA BLOCKERS</b>		
alfuzosin doxazosin tamsulosin terazosin	CARDURA (doxazosin) CARDURA XL (doxazosin) FLOMAX (tamsulosin) RAPAFLO (silodosin) silodosin TEZRULY SOLUTION (terazosin)*	Non-preferred alpha blockers require 30-day trials of at least two preferred agents in this subclass, including the generic formulation of the requested non-preferred agent before they will be approved, unless one of the exceptions on the PA form is present.  *Tezruly may only be authorized for those who are unable to ingest solid dosage forms of terazosin due to documented oral-motor difficulties or dysphagia.
<b>5-ALPHA-REDUCTASE (5AR) INHIBITORS/ALPHA BLOCKER COMBINATION</b>		
	dutasteride/tamsulosin JALYN (dutasteride/tamsulosin)	<b>Substitute for Class Criteria:</b> Concurrent 30-day trials of dutasteride and tamsulosin are required before the non-preferred agent will be authorized.
<b>BRONCHODILATORS, BETA AGONIST<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 30-day trials of each chemically distinct preferred agent in their corresponding subclass unless one of the exceptions on the PA form is present.		
<b>INHALATION SOLUTION</b>		
albuterol	arformoterol BROVANA (arformoterol) formoterol levalbuterol metaproterenol PERFOROMIST (formoterol) XOPENEX (levalbuterol)*	*Xopenex Inhalation Solution will be authorized for 12 months for a diagnosis of asthma or COPD for patients on concurrent asthma controller therapy (either oral or inhaled) with documentation of failure on a trial of albuterol or documented intolerance of albuterol, or for concurrent diagnosis of heart disease.

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>INHALERS, LONG-ACTING</b>		
SEREVENT (salmeterol)	STRIVERDI RESPIMAT (olodaterol)	
<b>INHALERS, SHORT-ACTING</b>		
albuterol HFA PROAIR HFA (albuterol) PROAIR RESPICLICK (albuterol) PROVENTIL HFA (albuterol) VENTOLIN HFA (albuterol)	PROAIR DIGIHALER (albuterol) XOPENEX HFA (levalbuterol)	*Airsupra can be found in Glucocorticoids, Inhaled section of PDL.
<b>ORAL</b>		
albuterol syrup	albuterol ER albuterol IR metaproterenol terbutaline	
<b>CALCIUM CHANNEL BLOCKERS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 14-day trials of each preferred agent within the corresponding subclass before they will be approved, unless one of the exceptions on the PA form is present.		
<b>LONG-ACTING</b>		
amlodipine diltiazem ER/CD felodipine ER nifedipine ER verapamil ER	CALAN SR (verapamil) DILT-XR diltiazem LA KATERZIA SUSPENSION (amlodipine)* levamlodipine maleate MATZIM LA (diltiazem) nisoldipine NORLIQVA (amlodipine)* NORVASC (amlodipine) PROCARDIA XL (nifedipine) SULAR (nisoldipine) verapamil ER PM VERELAN/VERELAN PM (verapamil)	*Katerzia and Norliqva may be authorized for children who are six to 10 years of age who are unable to ingest solid dosage forms. Therapy may be authorized for older patients with clinical documentation indicating oral-motor difficulties or dysphagia. In addition, Norliqva may only be authorized for patients who have a documented allergy or are unable to tolerate Katerzia.
<b>SHORT-ACTING</b>		
diltiazem verapamil	CARDIZEM (diltiazem) isradipine nicardipine nifedipine nimodipine NYMALIZE SOLUTION (nimodipine) PROCARDIA (nifedipine)	
<b>CEPHALOSPORINS AND RELATED ANTIBIOTICS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a five-day trial of a preferred agent within the corresponding subclass before they will be approved, unless one of the exceptions on the PA form is present.		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>BETA LACTAMS AND BETA LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS</b>		
amoxicillin/clavulanate IR	amoxicillin/clavulanate ER AUGMENTIN (amoxicillin/clavulanate)	
<b>CEPHALOSPORINS</b>		
cefaclor capsules cefadroxil tablets cefdinir cefuroxime tablets cephalexin capsules, suspension	cefaclor suspension cefaclor ER tablets cefadroxil capsules cefadroxil suspension cefixime cefpodoxime cefprozil cefuroxime suspension cephalexin tablets KEFLEX (cephalexin) SUPRAX (cefixime)	
<b>COPD AGENTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 60-day trial of one preferred agent from the corresponding subclass before they will be approved, unless one of the exceptions on the PA form is present.		
<b>ANTICHOLINERGIC<sup>AP</sup></b>		
ATROVENT HFA (ipratropium) INCRUSE ELLIPTA (umeclidinium) ipratropium nebulizer solution SPIRIVA HANDIHALER (tiotropium) SPIRIVA RESPIMAT (tiotropium)	TUDORZA (aclidinium) YUPELRI SOLUTION (revefenacin)	
<b>ANTICHOLINERGIC-BETA AGONIST COMBINATIONS<sup>AP</sup></b>		
albuterol/ipratropium nebulizer solution ANORO ELLIPTA (umeclidinium/vilanterol) COMBIVENT RESPIMAT (albuterol/ipratropium) STIOLTO RESPIMAT (tiotropium/olodaterol)	BEVESPI (glycopyrrolate/formoterol) DUAKLIR PRESSAIR (aclidinium/formoterol)* <b>umeclidinium/vilanterol</b>	<b>*In addition to the Class PA Criteria:</b> Duaklir Pressair requires 60-day trials of each long-acting preferred agent, as well as a 60-day trial of Stiolto Respimat.
<b>ANTICHOLINERGIC-BETA AGONIST-GLUCOCORTICOID COMBINATIONS</b>		
	BREZTRI AEROSPHERE (budesonide/glycopyrrolate/formoterol)* TRELEGY ELLIPTA (fluticasone/umeclidinium/vilanterol)**	*Breztri may be prior authorized for patients currently established on the individual components for at least 30 days.  **Trelegy Ellipta may be prior authorized for patients currently established on the individual components for at least 30 days.
<b>PHOSPHODIESTERASE INHIBITORS</b>		
roflumilast	DALIRESP (roflumilast) OHTUVAYRE (ensifentrine)*	*Ohtuvayre is being used for the maintenance treatment of patients with moderate to severe chronic obstructive

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		pulmonary disease (COPD) <b>AND</b> the patient has had a documented side effect, allergy, treatment failure, or a contraindication to maximally tolerated dual therapy with at least one inhaled long-acting muscarinic antagonist (LAMA) <b>AND</b> at least one inhaled long-acting beta-agonist (LABA) <b>OR</b> maximally tolerated triple therapy with at least one inhaled LAMA + LABA <b>AND</b> at least one inhaled corticosteroid (when blood eosinophils greater than or equal to ( $\geq$ ) 300 cells/microL).
<b>CROHNS DISEASE ORAL STEROIDS</b>		
<b>ORAL</b>		
budesonide ER capsules (generic ENTOCORT EC)	ENTOCORT EC (budesonide)* ORTIKOS (budesonide)*	*Please see the following PDL classes for PDL status of additional agents used for induction and remission (Cytokine and CAM Antagonists/Immunosuppressives, Oral/Ulcerative Colitis Agents).  *Entocort EC and Ortikos may only be authorized if the patient has a documented allergy, or intolerance, to the generic budesonide 3 mg 24-hour capsules.
<b>CYTOKINE &amp; CAM ANTAGONISTS<sup>CL/PA</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 90-day trials of all preferred agents which are indicated for the diagnosis, unless one of the exceptions on the PA form is present. <i>Patients stabilized for at least six months on their existing non-preferred regimen shall be grandfathered (provided the current therapy is for a labeled indication AND a more cost-effective biosimilar product is not available). In cases where a biosimilar exists but is also non-preferred, the PA vendor shall advise the provider which product is the most cost-effective agent. All off-label requests require review by the medical director. Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the link.</i>		
<b>ANTI-TNFs</b>		
adalimumab-fkjp AVSOLA (infliximab-axxq) ENBREL (etanercept) HADLIMA (adalimumab-bwwd) HUMIRA (adalimumab) infliximab SIMLANDI (adalimumab-ryvk) SIMPONI SUBCUTANEOUS (golimumab)	ABRILADA (adalimumab-afzb) adalimumab-aacf adalimumab-aaty adalimumab-adbm adalimumab-adaz AMJEVITA (adalimumab-atto) CIMZIA (certolizumab pegol) CYLTEZO (adalimumab-adbm) HULIO (adalimumab-fkjp) HYRIMOZ (adalimumab-adaz) IDACIO (adalimumab-aacf) INFLECTRA (infliximab-dyyb) REMICADE (infliximab) RENFLEXIS (infliximab-abda) YUFLYMA (adalimumab-aaty) YUSIMRY (adalimumab-aqvh) ZYMFENTRA (infliximab-dyyb)	

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>OTHERS</b>		
KINERET (anakinra) ORENCIA CLICKJECT, VIAL (abatacept) OTEZLA (apremilast) PYZCHIVA (ustekinumab-ttwe)*** TALTZ (ixekizumab)* TYENNE (tocilizumab-aazg) XELJANZ (tofacitinib)	ACTEMRA ACTPEN (tocilizumab) ACTEMRA SUBCUTANEOUS (tocilizumab) BIMZELX (bimekizumab-bkzx) COSENTYX (secukinumab) ENTYVIO (vedolizumab) ILARIS (canakinumab) ILUMYA (tildrakizumab) <b>IMULDOSA (ustekinumab-srlf)</b> KEVZARA (sarilumab) OLUMIANT (baricitinib) OMVOH (mirikizumab-mrkz) ORENCIA SYRINGE (abatacept) OTULFI (ustekinumab-aauz) RINVOQ ER (upadacitinib)** SELARSDI (ustekinumab-aekn) SKYRIZI (risankizumab-rzaa) SOTYKTU (deucravacitinib) STELARA SUBCUTANEOUS (ustekinumab) STEQEYMA (ustekinumab-stba) TOFIDENCE (tocilizumab-bavi) TREMFYA (guselkumab) VELSIPITY (etrasimod) WEZLANA (ustekinumab-auub) XELJANZ XR (tofacitinib) YESINTEK (ustekinumab-kfce)	<p>*Taltz will be authorized for treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis only after inadequate response to a 90-day trial of one preferred Anti-TNF agent.</p> <p>**Full PA criteria for Rinvoq ER may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.</p> <p>***In addition to class criteria, Pyzchiva may be authorized for a diagnosis of an FDA approved indication after a 90-day trial of one preferred Anti-TNF agent.</p>
<b>DIABETES AGENTS, BIGUANIDES</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 90-day trial of a preferred agent of similar duration before they will be approved, unless one of the exceptions on the PA form is present.		
metformin metformin ER (generic GLUCOPHAGE XR)	FORTAMET (metformin ER) GLUCOPHAGE XR (metformin ER) GLUMETZA (metformin ER)* metformin solution (generic RIOMET) metformin ER (generic GLUMETZA and FORTAMET) RIOMET (metformin)	*Glumetza will be approved only after a 30-day trial of Fortamet.
<b>DIABETES AGENTS, DPP-4 INHIBITORS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents are available only on appeal. <b>NOTE:</b> DPP-4 inhibitors will NOT be approved in combination with a GLP-1 agonist.		
JANUMET (sitagliptin/metformin) JANUMET XR (sitagliptin/metformin) JANUVIA (sitagliptin) JENTADUETO (linagliptin/metformin) TRADJENTA (linagliptin)	alogliptin alogliptin/metformin alogliptin/pioglitazone <b>BRYNOVIN SOLUTION (sitagliptin)</b> JENTADUETO XR (linagliptin/metformin)	



THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	KAZANO (alogliptin/metformin) KOMBIGLYZE XR (saxagliptin/metformin) NESINA (alogliptin) ONGLYZA (saxagliptin) OSENI (alogliptin/pioglitazone) sitagliptin sitagliptin/metformin ZITUVIO (sitagliptin) ZITUVIMET (sitagliptin/metformin) ZITUVIMET XR (sitagliptin/metformin)	
<b>DIABETES AGENTS, GLP-1 AGONISTS<sup>CL/PA</sup></b> <b>Preferred agents may be authorized with a diagnosis of Diabetes Mellitus Type II.</b>  <b>CLASS PA CRITERIA:</b> Non-preferred agents will only be approved (in six-month intervals) if ALL of the following criteria have been met: <ol style="list-style-type: none"> <li>1) Diagnosis of Diabetes Mellitus Type II.</li> <li>2) Current A1C must be submitted. Agents in this class will not be approved for patients with a starting A1C of less than (&lt;) 7%.</li> <li>3) Documentation demonstrating 90 days of compliance <u>on all current diabetic therapies</u> is provided.</li> <li>4) Documentation demonstrating treatment failure with all unique preferred agents in the same class.</li> </ol> <p>Re-authorizations will require documentation of <u>continued</u> compliance on all diabetic therapies and A1C levels must reach goal (either an A1C of less than or equal to (≤) 8% or demonstrated continued improvement).</p> <p><b>NOTE: GLP-1 agents will NOT be approved in combination with a DPP-4 inhibitor.</b></p>		
OZEMPIC (semaglutide) TRULICITY (dulaglutide) VICTOZA (liraglutide)	BYDUREON BCISE (exenatide) BYETTA (exenatide) liraglutide MOUNJARO (tirzepatide)	

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	RYBELSUS (semaglutide)	
<b>DIABETES AGENTS, INSULIN AND RELATED AGENTS</b>		
APIDRA (insulin glulisine) HUMALOG (insulin lispro) HUMALOG JR KWIKPEN (insulin lispro) HUMALOG KWIKPEN U-100 (insulin lispro) HUMALOG MIX PENS (insulin lispro/lispro protamine) HUMALOG MIX VIALS (insulin lispro/lispro protamine) HUMULIN 70/30 (insulin) HUMULIN R U-500 VIALS (insulin) HUMULIN R U-500 KWIKPEN (insulin) insulin aspart flexpen, penfill, vials insulin aspart/aspart protamine pens, vials  insulin lispro kwikpen U-100, vials LANTUS (insulin glargine) NOVOLOG (insulin aspart) NOVOLOG MIX (insulin aspart/aspart protamine) NOVOLIN N (insulin) SEMGLEE (insulin glargine) TOUJEO SOLOSTAR (insulin glargine) TOUJEO MAX SOLOSTAR (insulin glargine)	ADMELOG (insulin lispro) AFREZZA (insulin) <sup>CL/PA</sup> BASAGLAR (insulin glargine) FIASP (insulin aspart) HUMALOG U-200 KWIKPEN (insulin lispro) HUMULIN PENS (insulin) HUMULIN R VIAL (insulin) HUMULIN N VIAL (insulin) insulin glargine insulin lispro junior kwikpen insulin lispro protamine mix LYUMJEV (insulin lispro) MERILOG (insulin aspart-szjj) NOVOLIN (insulin) REZVOGLAR (insulin glargine-aglr) SOLIQUA (insulin glargine/lixisenatide)* TRESIBA (insulin degludec)** TRESIBA FLEXTOUCH (insulin degludec)** XULTOPHY (insulin degludec/liraglutide)*	<p>*Non-preferred insulin combination products require that the patient must already be established on the individual agents at doses not exceeding the maximum dose achievable with the combination product and require medical reasoning beyond convenience or enhanced compliance as to why the clinical need cannot be met with a combination of preferred single-ingredient agents.</p> <p>**Patients stabilized on Tresiba may be grandfathered <u>at the request of the prescriber</u> if the prescriber considers the preferred products to be clinically inappropriate.</p> <p>**Tresiba U-100 may be approved only for: Patients who have demonstrated at least a six-month history of compliance on a preferred long-acting insulin and who continue to have regular incidents of hypoglycemia.</p> <p>**Tresiba U-200 may be approved only for: Patients who require once daily doses of at least 60 units of long-acting insulin and have demonstrated at least a six-month history of compliance on preferred long-acting insulin and who continue to have regular incidents of hypoglycemia.</p>
<b>DIABETES AGENTS, MEGLITINIDES</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents are available only on appeal.		
<b>MEGLITINIDES</b>		
nateglinide repaglinide	PRANDIN (repaglinide) STARLIX (nateglinide)	
<b>MEGLITINIDE COMBINATIONS</b>		
	repaglinide/metformin	
<b>DIABETES AGENTS, MISCELLANEOUS AGENTS</b>		
<b>CLASS PA CRITERIA:</b> Welchol will be authorized for add-on therapy for Diabetes Mellitus Type II when there is a previous history of a 30-day trial of an oral diabetic agent.		
colesevelam	SYMLIN (pramlintide)* WELCHOL (colesevelam) <sup>AP</sup>	*Symlin will be authorized with a history of bolus insulin utilization in the past 90 days with no gaps in insulin therapy greater than (>) 30 days.
<b>DIABETES AGENTS, SGLT2 INHIBITORS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents will only be approved (in six-month intervals) if ALL of the following criteria have been met:		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
1) Current A1C must be submitted. Agents in this class will not be approved for patients with a starting A1C of less than (<) 7%. 2) Documentation demonstrating 90 days of compliance <u>on all current diabetic therapies</u> is provided. 3) Documentation demonstrating treatment failure with all unique preferred agents in the same class.  Re-authorizations will require documentation of <u>continued</u> compliance on all diabetic therapies and A1C levels must reach goal (either an A1C of less than or equal to ( $\leq$ ) 8% or demonstrated continued improvement).  <b>For all other FDA approved indications:</b> A 30-day trial and failure of each preferred SGLT2 is required.		
<b>SGLT2 INHIBITORS</b>		
FARXIGA (dapagliflozin) JARDIANCE (empagliflozin)	dapagliflozin INVOKANA (canagliflozin) STEGLATRO (ertugliflozin)	
<b>SGLT2 COMBINATIONS</b>		
GLYXAMBI (empagliflozin/linagliptin) SYNJARDY (empagliflozin/metformin) SYNJARDY XR (empagliflozin/metformin) TRIJARDY XR (empagliflozin/linagliptin/metformin) XIGDUO XR (dapagliflozin/metformin)	dapagliflozin/metformin INVOKAMET (canagliflozin/metformin) INVOKAMET XR (canagliflozin/metformin) QTERN (dapagliflozin/saxagliptin) SEGLUROMET (ertugliflozin/metformin) STEGLUJAN (ertugliflozin/sitagliptin)	
<b>DIABETES AGENTS, TZD</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents are available only on appeal.		
<b>THIAZOLIDINEDIONES</b>		
pioglitazone	ACTOS (pioglitazone) AVANDIA (rosiglitazone)	
<b>TZD COMBINATIONS</b>		
	ACTOPLUS MET (pioglitazone/metformin)* DUETACT (pioglitazone/glimepiride)* pioglitazone/glimepiride pioglitazone/metformin	*Patients are required to use the components of Actoplus Met and Duetact separately. Exceptions will be handled on a case-by-case basis.
<b>DUCHENNE MUSCULAR DYSTROPHY (DMD), CORTICOSTEROIDS</b>		
<b>CLASS PA CRITERIA:</b>		
AGAMREE (vamorolone) EMFLAZA (deflazacort)	deflazacort JAYTHARI (deflazacort)	
<b>DRY EYE PRODUCTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 60-day trial of the preferred agent(s).		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
RESTASIS (cyclosporine) XIIDRA (lifitegrast)	CEQUA (cyclosporine) cyclosporine dropperette MIEBO RESTASIS MULTIDOSE (cyclosporine)* TYRVAYA (varenicline) <b>TRYPTYR (acoltremone)</b> VEVYE (cyclosporine)	*Restasis Multidose is approvable only on appeal and requires medical reasoning as to why the clinical need cannot be met with the preferred product (Restasis).
<b>EPINEPHRINE, SELF-ADMINISTERED</b>		
<b>CLASS PA CRITERIA:</b> A non-preferred agent may be authorized with documentation showing the patient's inability to follow the instructions, or the patient's failure to understand the training for the preferred agent(s).		
epinephrine (labeler 49502 only) EPIPEN (epinephrine) EPIPEN JR (epinephrine)	AUVI-Q (epinephrine) epinephrine (all labelers except 49502) NEFFY NASAL SPRAY (epinephrine) SYMJEPI (epinephrine)	
<b>ERYTHROPOIESIS STIMULATING PROTEINS<sup>CL/PA</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 30-day trial of a preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
EPOGEN (rHuEPO) RETACRIT (epoetin alpha)	ARANESP (darbepoetin) MIRCERA (methoxy PEG-epoetin) PROCRT (rHuEPO)	Erythropoiesis agents will be authorized if the following criteria are met: <ol style="list-style-type: none"> <li>1. Hemoglobin or hematocrit less than (&lt;) 10/30 respectively. For renewal, hemoglobin or hematocrit levels greater than (&gt;) 12/36 will require dosage reduction or discontinuation. Exceptions will be considered on an individual basis after medical documentation is reviewed (laboratory values must be dated within six weeks of request); <b>AND</b></li> <li>2. Transferrin saturation greater than or equal to (≥) 20%, ferritin levels greater than or equal to (≥) 100 mg/ml, or on concurrent therapeutic iron therapy (laboratory values must be dated within three weeks of request). For re-authorization, transferrin saturation or ferritin levels are not required if the patient has been responsive to the erythropoietin agent; <b>AND</b></li> <li>3. For HIV-infected patients, endogenous serum erythropoietin level must be less than or equal to (≤) 500 mU/ml to initiate therapy; <b>AND</b></li> <li>4. No evidence of untreated GI bleeding, hemolysis, or Vitamin B-12, iron or folate deficiency.</li> </ol>

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>FLUOROQUINOLONES, ORAL<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a five-day trial of a preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
CIPRO SUSPENSION (ciprofloxacin) ciprofloxacin levofloxacin tablets	BAXDELA (delafloxacin) CIPRO TABLETS (ciprofloxacin) ciprofloxacin suspension levofloxacin solution moxifloxacin ofloxacin	
<b>GLUCOCORTICOIDS, INHALED<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 30-day trials of each chemically unique preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
<b>GLUCOCORTICOIDS</b>		
ARNUITY ELLIPTA (fluticasone) ASMANEX TWISTHALER (mometasone) budesonide nebulizer 0.5 mg/2 ml and 0.25 mg/2 ml solution PULMICORT FLEXHALER (budesonide)	ALVESCO (ciclesonide) ARMONAIR DIGIHALER (fluticasone) ASMANEX HFA (mometasone)* budesonide nebulizer solution 1 mg/2 ml fluticasone HFA* PULMICORT NEBULIZER SOLUTION (budesonide) QVAR REDIHALER (beclomethasone)	*Asmanex HFA and fluticasone HFA are approved for children less than or equal to ( $\leq$ ) 10 years of age.
<b>GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS</b>		
ADVAIR DISKUS (fluticasone/salmeterol) ADVAIR HFA (fluticasone/salmeterol) DULERA (mometasone/formoterol) SYMBICORT (budesonide/formoterol)	AIRDUO DIGIHALER (fluticasone/salmeterol) AIRDUO RESPICLICK (fluticasone/salmeterol) AIRSUPRA (albuterol/budesonide) BREO ELLIPTA (fluticasone/vilanterol) budesonide/formoterol fluticasone/salmeterol fluticasone/vilanterol WIXELA (fluticasone/salmeterol)	
<b>GROWTH HORMONES AND ACHONDROPLASIA AGENTS<sup>CL/PA</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require three-month trials of each preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
GENOTROPIN (somatropin) NORDITROPIN (somatropin)	HUMATROPE (somatropin) INCRELEX (mecasermin) NGENLA (somatrogon-ghla) NUTROPIN AQ (somatropin) OMNITROPE (somatropin) SAIZEN (somatropin) SEROSTIM (somatropin) SKYTROFA (lonapegsomatropin) SOGROYA (somapacitan-beco) VOXZOGO (vosoritide)* ZOMACTON (somatropin) ZORBTIVE (somatropin)	Patients already on a non-preferred agent will receive authorization to continue therapy on that agent for the duration of the existing PA.  *Full PA criteria for Voxzogo may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>H. PYLORI TREATMENT</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a trial of the combination of individual preferred components of the requested non-preferred agent and must be used at the recommended dosages, frequencies, and duration of the non-preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
Please use individual components: 1. preferred PPI (omeprazole or pantoprazole) 2. amoxicillin 3. tetracycline capsules 4. metronidazole 5. clarithromycin 6. bismuth PYLERA (bismuth/metronidazole/tetracycline)	HELIDAC (bismuth/metronidazole/tetracycline) lansoprazole/amoxicillin/clarithromycin OMECLAMOX-PAK (omeprazole/amoxicillin/clarithromycin) TALICIA (omeprazole/amoxicillin/rifabutin) tetracycline tablets VOQUEZNA DUAL PAK (vonoprazan/amoxicillin) VOQUEZNA TRIPLE PAK (vonoprazan/amoxicillin/clarithromycin)	
<b>HEART FAILURE TREATMENTS</b>		
This is not an all-inclusive list of agents available for the treatment of heart failure. Please see beta blockers and SGLT-2 agents.		
sacubitril/valsartan	ENTRESTO SPRINKLE CAPSULES (sacubitril/valsartan)** <b>KERENDIA (finerenone)</b> INPEFA (sotagliflozin)*** <b>ENTRESTO (sacubitril/valsartan)</b> VERQUVO (vericiguat)****	*Entresto may be authorized only for patients greater than or equal to (≥) one year of age diagnosed with chronic heart failure  **Entresto sprinkle capsules may be authorized for children who are one to nine years of age who are unable to ingest solid dosage forms. Therapy may be authorized for older patients with clinical documentation indicating oral-motor difficulties or dysphagia.  ***Inpefa may be authorized for an FDA approved indication <b>AND</b> clinical reasoning must be provided as to why the medical need cannot be met with a preferred SGLT2 agent.

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		****Full PA criteria for Verquvo may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>HEPATITIS B TREATMENTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 90-day trials of each preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
BARACLUDE SOLUTION (entecavir)* entecavir lamivudine HBV	adefovir BARACLUDE TABLETS (entecavir) EPIVIR HBV (lamivudine) HEPSERA (adefovir) VEMLIDY (tenofovir alafenamide)	*Baraclude <u>solution</u> will be authorized only for patients with documentation of dysphagia.
<b>HEPATITIS C TREATMENTS</b> <sup>CL/PA</sup>		
<b>CLASS PA CRITERIA:</b> For patients starting therapy in this class, preferred regimens may be found on the <a href="#">PA Criteria</a> page. Requests for non-preferred regimens require medical reasoning why a preferred regimen cannot be used.		
MAVYRET (pibrentasvir/glecaprevir)* ribavirin sofosbuvir/velpatasvir (labeler 72626)*	EPCLUSA (sofosbuvir/velpatasvir)* HARVONI (ledipasvir/sofosbuvir)* ledipasvir/sofosbuvir* PEGASYS (pegylated interferon) PEG-INTRON (pegylated interferon) RIBASPHERE RIBAPAK (ribavirin) RIBASPHERE 400 mg and 600 mg (ribavirin) SOVALDI (sofosbuvir)* VIEKIRA XR (dasabuvir/ombitasvir/paritaprevir/ritonavir)* VOSEVI (sofosbuvir/velpatasvir/voxilaprevir) ZEPATIER (elbasvir/grazoprevir)	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>HYPERPARATHYROID AGENTS</b> <sup>AP</sup>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 30-day trials of each preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
cinacalcet paricalcitol capsules	doxercalciferol HECTOROL (doxercalciferol) paricalcitol injection RAYALDEE (calcifediol) SENSIPAR (cinacalcet) ZEMPLAR (paricalcitol)	
<b>HYPERPHOSPHATEMIA AGENTS</b> <sup>AP</sup>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 30-day trial of at least two preferred agents, one of which must be sevelamer carbonate unless one of the exceptions on the PA form is present.		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
calcium acetate capsules CALPHRON (calcium acetate) MAGNEBIND RX (calcium carbonate/folic acid/magnesium carbonate) sevelamer carbonate	AURYXIA (ferric citrate) calcium acetate tablets FOSRENOL (lanthanum) lanthanum chewable tablets RENAGEL (sevelamer) RENVELA (sevelamer carbonate) sevelamer carbonate powder packet sevelamer HCl VELPHORO (sucroferric oxyhydroxide) XPHOZAH (tenapanor)*	*One additional 30-day trial of a non-preferred phosphate binder (such as ferric citrate, lanthanum, or Velphoro) is required prior to Xphozah approval.
<b>HYPOGLYCEMIA TREATMENTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require clinical reasoning beyond convenience why the preferred glucagon products cannot be used.		
BAQSIMI SPRAY (glucagon) glucagon vial glucagon emergency kit GVOKE (glucagon) ZEGALOGUE (dasiglucagon)	GLUCAGEN HYPOKIT (glucagon)	
<b>HYPOPARATHYROID AGENTS</b>		
	YORVIPATH (palopegteriparatide)*	*Yorvipath may be approvable for adult patients diagnosed with hypoparathyroidism who have documentation supporting the inability to achieve disease control with conventional therapies such as prescribed calcium supplements and prescribed active forms of vitamin D.
<b>IMMUNOMODULATORS, ATOPIC DERMATITIS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 30-day trial of a medium-to-high potency topical corticosteroid <b>AND all</b> preferred agents in this class unless one of the exceptions on the PA form is present. Requirement for topical corticosteroids may be excluded with involvement of sensitive areas such as the face and skin folds.		
<b>SYSTEMIC TREATMENTS</b>		
ADBRY (tralokinumab)* DUPIXENT (dupilumab)* EBGLYSS (lebrikizumab)	CIBINQO (abrocitinib)* NEMLUVIO (nemolizumab-ilto)*	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink
<b>TOPICAL TREATMENTS</b>		
OPZELURA CREAM (ruxolitinib)* tacrolimus ointment	EUCRISA (crisaborole) <sup>AP**</sup> pimecrolimus cream VTAMA (tapinarof) ZORYVE 0.15% CREAM (roflumilast)***	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink  **Eucrisa requires a 30-day trial of tacrolimus <b>OR</b> a medium to high potency corticosteroid unless contraindicated.



THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		***Zoryve 0.15% cream for atopic dermatitis requires 30-day trials each of a medium to high potency topical corticosteroid AND tacrolimus ointment
<b>IMMUNOMODULATORS, GENITAL WARTS &amp; ACTINIC KERATOSIS AGENTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 30-day trials of each preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
CONDYLOX GEL (podofilox) fluorouracil 5% cream imiquimod cream	ALDARA (imiquimod) diclofenac 3% gel fluorouracil 0.5% cream imiquimod pump podofilox VEREGEN (sinecatechins)	*Zyclara will be authorized for a diagnosis of actinic keratosis.
<b>IMMUNOSUPPRESSIVES, ORAL</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 14-day trial of a preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
azathioprine cyclosporine cyclosporine, modified mycophenolate mofetil sirolimus tacrolimus capsules	ASTAGRAF XL (tacrolimus) CELLCEPT (mycophenolate mofetil) ENVARUS XR (tacrolimus) everolimus tablets IMURAN (azathioprine) LUPKYNIS (voclosporin)* mycophenolic acid mycophenolic mofetil suspension MYFORTIC (mycophenolic acid) MYHIBBIN (mycophenolate mofetil suspension)*** NEORAL (cyclosporine, modified) PROGRAF (tacrolimus) RAPAMUNE (sirolimus) REZUROCK (belumosudil)** SANDIMMUNE (cyclosporine) ZORTRESS (everolimus)	*Lupkynis requires a 90-day trial of Benlysta prior to approval. Full PA criteria for Lupkynis may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.  **Rezurock may be authorized after a trial of two systemic treatments for chronic graft-versus-host disease. Examples of systemic therapy may include methylprednisolone, Imbruvica (ibrutinib capsules and tablets), cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil and imatinib.  ***Myhibbin may be authorized for those who are unable to ingest solid dosage forms due to documented oral-motor difficulties or dysphagia AND documentation is provided as to why the clinical need cannot be met with mycophenolate suspension.
<b>INTRANASAL RHINITIS AGENTS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> See below for individual subclass criteria.		
<b>ANTICHOLINERGICS</b>		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ipratropium	ATROVENT (ipratropium)	Non-preferred agents require 30-day trials of one preferred nasal anti-cholinergic agent, <b>AND</b> one preferred antihistamine, <b>AND</b> one preferred intranasal corticosteroid agent before they will be approved, unless one of the exceptions on the PA form is present.
<b>ANTIHISTAMINES</b>		
azelastine olopatadine	PATANASE (olopatadine)	
<b>COMBINATIONS</b>		
	azelastine/fluticasone DYMISTA (azelastine/fluticasone)* RYALTRIS (olopatadine HCl/mometasone)**	*Dymista requires a concurrent 30-day trial of each preferred component before it will be approved, unless one of the exceptions on the PA form is present.  **Ryaltris requires a 30-day trial of each individual component before it may be approved.
<b>CORTICOSTEROIDS</b>		
fluticasone propionate OMNARIS (ciclesonide) QNASL HFA (beclomethasone)	BECONASE AQ (beclomethasone) flunisolide mometasone NASONEX (mometasone)	Non-preferred agents require 30-day trials of each preferred agent in this subclass before they will be approved, unless one of the exceptions on the PA form is present.
<b>IRRITABLE BOWEL SYNDROME/SHORT BOWEL SYNDROME/SELECTED GI AGENTS</b>		
<b>CLASS PA CRITERIA:</b> All agents are approvable only for patients 18 years of age and older. <b>See below for additional subclass criteria.</b>		
<b>CONSTIPATION</b>		
LINZESS 145 mcg and 290 mcg (linaclotide) lubiprostone capsules MOVANTIK (naloxegol)	AMITIZA (lubiprostone) IBSRELA (tenapanor) LINZESS 72 mcg (linaclotide) MOTEGRITY (prucalopride) SYMPROIC (naldemedine)	No agent shall be approved to treat opioid induced constipation (OIC) without evidence of at least 90 days of opioid use preceding the request. Continuation of coverage shall be granted with evidence of continuous and concurrent opioid use.  <b>Agents may be authorized only for their FDA approved labeled indication. The following agent-specific criteria shall also apply, unless one of the exceptions on the PA form is present:</b>  <u>Ibsrela</u> requires 30-day trials of each preferred agent for IBS-C, however for <u>males</u> , a trial of lubiprostone is not required.  <u>Linzess 72 mcg</u> may only be approved for a diagnosis of chronic idiopathic constipation (CIC) AND for those who cannot tolerate the 145 mcg dose. Linzess may

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		<p>also be approvable for a diagnosis of functional constipation for pediatric patients six to 17 years of age.</p> <p><b>Motegrity</b> requires a 30-day trial of both lubiprostone and Linzess.</p> <p><b>Symproic</b> is indicated for OIC and requires 30-day trial of both Movantik and lubiprostone.</p>
DIARRHEA		
	alosetron LOTRONEX (alosetron) MYTESI (crofelemer) VIBERZI (eluxadoline)	Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
LAXATIVES AND CATHARTICS		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require trials of each preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
CLENPIQ (sodium picosulfate/magnesium oxide/citric acid) COLYTE GOLYTELY NULYTELY peg 3350 sod sulfate-pot sulf-mag sulf (generic) SUPREP	peg 3350-sod sulf-NaCL-KCL-asb powder SUFLAVE (peg 350-sod sulf, chl-pot-mag) SUPREP SUTAB (magnesium sulfate/potassium sulfate/sodium sulfate)	
LEUKOTRIENE MODIFIERS		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 30-day trials of each preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
montelukast zafirlukast	ACCOLATE (zafirlukast) SINGULAIR (montelukast) zileuton ZYFLO (zileuton)	
LIPOTROPICS, OTHER (Non-statins)		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 12-week trial of a preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
APOC-III-DIRECTED ASO		
	TRYNGOLZA (olezarsen)*	*Full criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>BEMPEDOIC ACIDS</b>		
	NEXLIZET (bempedoic acid/ezetimibe)* NEXLETOL (bempedoic acid)*	*Full criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>BILE ACID SEQUESTRANTS<sup>AP</sup></b>		
cholestyramine colesevelam colestipol tablets	COLESTID (colestipol) colestipol granules QUESTRAN (cholestyramine) WELCHOL (colesevelam)*	*Welchol will be authorized for add-on therapy for Diabetes Mellitus Type II when there is a previous history of a 30-day trial of an oral agent (metformin, sulfonylurea, or thiazolidinedione (TZD)). See HYPOGLYCEMICS, MISCELLANEOUS.
<b>CHOLESTEROL ABSORPTION INHIBITORS</b>		
ezetimibe	ZETIA (ezetimibe)	
<b>FATTY ACIDS</b>		
omega-3 acid ethyl esters	icosapent ethyl capsules LOVAZA (omega-3-acid ethyl esters)	Icosapent ethyl capsules may be approved if the following criteria are met (A or B): A. The patient has a triglyceride level of at least 500 mg/dL and has previously completed at least a 12-week trial on omega-3 acid ethyl esters; <b>OR</b> B. The patient has an initial triglyceride level of at least 150 mg/dL; <b>AND</b> The patient has either established cardiovascular disease or diabetes; <b>AND</b> The patient will be concurrently receiving a statin.
<b>FIBRIC ACID DERIVATIVES<sup>AP</sup></b>		
fenofibrate 54 mg and 160 mg fenofibrate micronized 67 mg, 134 mg and 200 mg fenofibrate nanocrystallized 48 mg and 145 mg gemfibrozil	ANTARA (fenofibrate) fenofibrate 40 mg tablets fenofibrate 150 mg capsules fenofibrate 43 mg, 50 mg, 120 mg and 130 mg fenofibrate micronized 30 mg and 90 mg fenofibric acid FENOGLIDE (fenofibrate) FIBRICOR (fenofibric acid) LIPOFEN (fenofibrate) LOPID (gemfibrozil) TRICOR (fenofibrate nanocrystallized) TRILIPIX (fenofibric acid)	
<b>MTP INHIBITORS</b>		
	JUXTAPID (lomitapide)*	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>PCSK-9 INHIBITORS</b>		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
PRALUENT (alirocumab)* REPATHA (evolocumab)*	LEQVIO (inclisiran)*	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>LIPOTROPICS, STATINS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> See below for individual subclass criteria.		
<b>STATINS</b>		
atorvastatin lovastatin pravastatin rosuvastatin simvastatin**	ALTOPREV (lovastatin) ATORVALIQ (atorvastatin)*** CRESTOR (rosuvastatin) EZALLOR SPRINKLE (rosuvastatin)* fluvastatin fluvastatin ER LESCOL XL (fluvastatin) LIPITOR (atorvastatin) LIVALO (pitavastatin) PRAVACHOL (pravastatin) ZOCOR (simvastatin)** ZYPITAMAG (pitavastatin)	Non-preferred agents require 12-week trials of two preferred agents, including the generic formulation of the requested non-preferred agent, before they will be approved, unless one of the exceptions on the PA form is present.  *Ezallor sprinkle will only be authorized for those who are unable to ingest solid dosage forms due to documented oral-motor difficulties or dysphagia.  **Zocor/simvastatin 80 mg tablets will require a clinical PA.  ***Atorvaliq may be authorized for children who are six to 10 years of age who are unable to ingest solid dosage forms. Therapy may be authorized for older patients with clinical documentation indicating oral-motor difficulties or dysphagia.
<b>STATIN COMBINATIONS</b>		
	amlodipine/atorvastatin CADUET (atorvastatin/amlodipine) ezetimibe/simvastatin* VYTORIN (simvastatin/ezetimibe)*	Non-preferred agents require 30-day concurrent trials of the corresponding preferred single agents before they will be approved, unless one of the exceptions on the PA form is present.  *Vytorin will be authorized only after an insufficient response to a 12-week trial of the maximum tolerable dose of atorvastatin or rosuvastatin, unless one of the exceptions on the PA form is present. Vytorin 80/10 mg tablets will require a clinical PA.
<b>MABS, ANTI-IL/IgE</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 90-day trials of all preferred agents which are indicated for the diagnosis. <b>Full PA Criteria may be found on the <a href="#">PA Criteria</a> page by clicking the link.</b>		
DUPIXENT (dupilumab) FASENRA (benralizumab) NUCALA AUTOINJECTOR, SYRINGE (mepolizumab) XOLAIR VIAL (omalizumab)	NUCALA VIAL (mepolizumab) TEZSPIRE (tezepelumab-ekko) XOLAIR SYRINGES (omalizumab)	

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>MAJOR ADVERSE CARDIOVASCULAR EVENT (MACE) REDUCTION AGENTS, GLP-1 AGONISTS</b>		
<b>CLASS PA CRITERIA:</b> *Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.		
WEGOVY		
<b>MACROLIDES</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a five-day trial of each preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
<b>MACROLIDES</b>		
azithromycin packet, suspension, tablets clarithromycin tablets	clarithromycin ER clarithromycin suspension E.E.S. (erythromycin ethylsuccinate) ERYPED (erythromycin ethylsuccinate) ERY-TAB (erythromycin) ERYTHROCIN (erythromycin stearate) erythromycin tablets/capsules DR erythromycin tablets erythromycin estolate ZITHROMAX (azithromycin)	
<b>METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), GLP-1 AGONISTS</b>		
<b>CLASS PA CRITERIA:</b> *Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.		
WEGOVY	REZDIFFRA (remetirom)	
<b>MULTIPLE SCLEROSIS AGENTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 90-day trials of two chemically unique preferred agents (in the same subclass) before they will be approved, unless one of the exceptions on the PA form is present.		
<b>INTERFERONS<sup>AP</sup></b>		
AVONEX (interferon beta-1a) AVONEX PEN (interferon beta-1a) BETASERON (interferon beta-1b) REBIF (interferon beta-1a) REBIF REBIDOSE (interferon beta-1a)	EXTAVIA KIT (interferon beta-1b) EXTAVIA VIAL (interferon beta-1b) PLEGRIDY (peginterferon beta-1a)	
<b>NON-INTERFERONS</b>		
COPAXONE 20 mg (glatiramer) dalfampridine ER dimethyl fumarate fingolimod KESIMPTA INJECTION (ofatumumab)* teriflunomide	AMPYRA (dalfampridine) AUBAGIO (teriflunomide) BAFIERTAM CAPSULES (monomethyl fumarate) COPAXONE 40 mg (glatiramer)** GILENYA (fingolimod) glatiramer GLATOPA (glatiramer)	*Kesimpta may be approved with documentation of treatment failure/inadequate treatment response after a 90-day trial of at least one preferred MS agent. Documentation of a negative Hepatitis B test must be provided.

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	MAVENCLAD (cladribine) MAYZENT (siponimod)*** PONVORY (ponesimod) TASCENSO ODT (fingolimod lauryl sulfate) TECFIDERA (dimethyl fumarate)*** VUMERITY (diroximel fumarate) ZEPOSIA (ozanimod)	**Copaxone 40 mg will only be authorized for documented injection site issues.  ***Mayzent may be authorized with no additional requirement beyond the diagnosis for patients with documented <u>secondary progressive MS</u> .
<b>NEUROPATHIC PAIN</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 30-day trial of a preferred agent in the corresponding dosage form (oral or topical) before they will be approved, unless one of the exceptions on the PA form is present.		
capsaicin (OTC) duloxetine gabapentin lidocaine patch 5% LYRICA CAPSULES, SOLUTION (pregabalin) pregabalin capsules	CYMBALTA (duloxetine) DRIZALMA SPRINKLE (duloxetine)* gabapentin ER (generic Gralise) GRALISE (gabapentin)** HORIZANT (gabapentin)*** lidocaine patch 4% LIDODERM (lidocaine) LYRICA CR (pregabalin)**** NEURONTIN (gabapentin) pregabalin ER tablets (generic LYRICA CR) pregabalin solution SAVELLA (milnacipran)***** ZTLIDO PATCH (lidocaine)	*Drizalma sprinkle will only be authorized for those who are unable to ingest solid dosage forms due to documented oral-motor difficulties or dysphagia.  **Gralise will be authorized only if the following criteria are met: <ol style="list-style-type: none"> <li>1. Diagnosis of postherpetic neuralgia; <b>AND</b></li> <li>2. Trial of a tricyclic antidepressant for at least 30-days; <b>AND</b></li> <li>3. Ninety-day trial of gabapentin immediate release formulation (positive response without adequate duration); <b>AND</b></li> <li>4. The request is for once daily dosing with 1800 mg maximum daily dosage.</li> </ol> ***Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.  ****Lyrica CR requires medical reasoning beyond convenience as to why the need cannot be met using preferred pregabalin capsules.  *****Savella will be authorized for a diagnosis of fibromyalgia only after a 90-day trial of one preferred agent.
<b>NSAIDS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> See below for subclass PA criteria.		
<b>NON-SELECTIVE</b>		
diclofenac (IR, SR) flurbiprofen ibuprofen capsules, chewable tablets,	DAYPRO (oxaprozin) diclofenac potassium capsules, tablets diflunisal	Non-preferred agents require 30-day trials of each preferred agent before they will be approved, unless one of the exceptions on the PA form is present.

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
suspension, tablets (Rx, OTC) indomethacin ketoprofen ketorolac meloxicam tablets nabumetone naproxen sodium capsules, tablets naproxen sodium DS tablets piroxicam sulindac	EC-naproxen DR tablets etodolac IR etodolac SR famotidine/ibuprofen FELDENE (piroxicam) fenoprofen INDOCIN SUSPENSION (indomethacin) INDOCIN SUPPOSITORIES (indomethacin) indomethacin ER ketoprofen ER ketorolac spray LOFENA (diclofenac) meclofenamate mefenamic acid meloxicam submicronized capsules (generic VIVLODEX) meloxicam suspension MOBIC TABLETS (meloxicam) NALFON (fenoprofen) NAPRELAN (naproxen) naproxen suspension naproxen CR oxaprozin RELAFEN DS (nabumetone) SPRIX (ketorolac) TIVORBEX (indomethacin) tolmetin VIVLODEX (meloxicam) VOLTAREN (diclofenac) ZIPSOR (diclofenac potassium) ZORVOLEX (diclofenac)	
<b>NSAID/GI PROTECTANT COMBINATIONS</b>		
	ARTHROTEC (diclofenac/misoprostol) diclofenac/misoprostol ibuprofen/famotidine naproxen/esomeprazole VIMOVO (naproxen/esomeprazole)	Non-preferred agents are only available on appeal and require medical reasoning beyond convenience as to why the need cannot be met with the combination of preferred single agents.
<b>COX-II SELECTIVE</b>		
celecoxib	CELEBREX (celecoxib)	
<b>TOPICAL</b>		
diclofenac gel (Rx)*	diclofenac patch diclofenac solution	Non-preferred agents require a 30-day trial of the preferred topical agent and 30-day trials of each



THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	LICART PATCH (diclofenac) PENNSAID (diclofenac)	preferred oral NSAID before they will be approved, unless one of the exceptions on the PA form is present.  *Diclofenac gel will be limited to 100 grams per month.
<b>OBSTRUCTIVE SLEEP APNEA AGENTS</b>		
<b>CLASS PA CRITERIA:</b> ZEPBOUND (tirzepatide)*		
		*Full criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>OPHTHALMIC ANTIBIOTICS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require three-day trials of each preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
bacitracin/polymyxin ointment ciprofloxacin* erythromycin gentamicin moxifloxacin* neomycin/bacitracin/polymyxin ofloxacin* polymyxin/trimethoprim tobramycin TOBREX OINTMENT (tobramycin)	AZASITE (azithromycin) bacitracin BESIVANCE (besifloxacin)* BLEPH-10 (sulfacetamide) CILOXAN (ciprofloxacin)* gatifloxacin* neomycin/polymyxin/gramicidin OCUFLOX (ofloxacin)* POLYTRIM (polymyxin/trimethoprim) sulfacetamide drops sulfacetamide ointment TOBREX (tobramycin) VIGAMOX (moxifloxacin)* XDEMVY (lotilaner)** ZYMAXID (gatifloxacin)*	*Prior authorization of any fluoroquinolone agent requires three-day trials of all other preferred agents unless definitive laboratory cultures exist indicating the need to use a fluoroquinolone.  **Xdemvy may be authorized for the treatment of demodex blepharitis without further restrictions.
<b>OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require three-day trials of each preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
MAXITROL OINTMENT, SUSPENSION (neomycin/polymyxin/dexamethasone) neomycin/bacitracin/polymyxin/hydrocortisone neomycin/polymyxin/dexamethasone PRED-G SUSPENSION (prednisolone/gentamicin) sulfacetamide/prednisolone TOBRADEX OINTMENT (tobramycin/dexamethasone) TOBRADEX SUSPENSION (tobramycin/dexamethasone) TOBRADEX ST (tobramycin/ dexamethasone)	neomycin/polymyxin/hydrocortisone PRED-G OINTMENT (prednisolone/gentamicin)	

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
tobramycin/dexamethasone suspension ZYLET (loteprednol/tobramycin)		
<b>OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 30-day trials of three preferred chemically-unique agents before they will be approved, unless one of the exceptions on the PA form is present.		
ALAWAY (ketotifen) ALREX (loteprednol) azelastine BEPREVE (bepotastine) cromolyn EYSUVIS (loteprednol) ketotifen ZADITOR (OTC) (ketotifen)	ALOCRIL (nedocromil) ALOMIDE (lodoxamide) bepotastine epinastine loteprednol LUMIFY (brimonidine) olopatadine 0.1% olopatadine 0.2% PATADAY ONCE and TWICE DAILY (olopatadine) ZERVIAE (cetirizine)	
<b>OPHTHALMICS, ANTI-INFLAMMATORIES</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require five-day trials of at least two preferred agents before they will be approved, unless one of the exceptions on the PA form is present. Trials must include at least one agent with the same mechanism of action as the requested non-preferred agent.		
dexamethasone diclofenac DUREZOL (difluprednate) FLAREX (fluorometholone) FML (fluorometholone) FML FORTE (fluorometholone) FML S.O.P. (fluorometholone) ketorolac LOTEMAX GEL, OINTMENT, SUSPENSION (loteprednol) MAXIDEX (dexamethasone) NEVANAC (nepafenac) PRED FORTE (prednisolone) PRED MILD (prednisolone) prednisolone acetate prednisolone sodium phosphate	ACULAR (ketorolac) ACULAR LS (ketorolac) ACUVAIL (ketorolac tromethamine) bromfenac BROMSITE (bromfenac) difluprednate fluorometholone flurbiprofen ILEVRO (nepafenac) INVELTYS (loteprednol) LOTEMAX SM (loteprednol etabonate) loteprednol drops, gel OMNIPRED (prednisolone) OZURDEX (dexamethasone) PROLENSA (bromfenac) RETISERT (fluocinolone) TRIESENCE (triamcinolone)	
<b>OPHTHALMICS, GLAUCOMA AGENTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents will only be authorized if there is an allergy to all preferred agents in the corresponding subclass.		
<b>COMBINATION AGENTS</b>		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
COMBIGAN (brimonidine/timolol) dorzolamide/timolol SIMBRINZA (brinzolamide/brimonidine)	brimonidine-timolol COSOPT PF (dorzolamide/timolol)	
<b>BETA BLOCKERS</b>		
BETOPTIC S (betaxolol) carteolol levobunolol timolol drops	betaxolol ISTALOL (timolol) timolol gel TIMOPTIC (timolol)	
<b>CARBONIC ANHYDRASE INHIBITORS</b>		
AZOPT (brinzolamide) dorzolamide	brinzolamide TRUSOPT (dorzolamide)	
<b>PARASYMPATHOMIMETICS</b>		
pilocarpine		
<b>PROSTAGLANDIN ANALOGS</b>		
latanoprost TRAVATAN-Z (travoprost)	bimatoprost IYUZEH (latanoprost) LUMIGAN (bimatoprost) tafluprost travoprost VYZULTA (latanoprostene)* XALATAN (latanoprost) XELPROS (latanoprost) ZIOPTAN (tafluprost)	*Vyzulta prior authorization requires failure on a three-month trial of at least one preferred prostaglandin eye drop used in combination with an agent from another subclass.
<b>RHO-KINASE INHIBITORS</b>		
RHOPRESSA (netarsudil) ROCKLATAN (netarsudil/latanoprost)		
<b>SYMPATHOMIMETICS</b>		
ALPHAGAN P SOLUTION (brimonidine) brimonidine 0.2%	apraclonidine brimonidine 0.15% IOPIDINE (apraclonidine)	
<b>OPIATE DEPENDENCE TREATMENTS</b>		
<b>CLASS PA CRITERIA:</b> Bunavail and Zubsolv may only be approved with a documented intolerance or allergy to Suboxone films AND buprenorphine/naloxone tablets.		
BRIXADI (buprenorphine) <sup>CL/PA</sup> buprenorphine/naloxone tablets KLOXXADO SPRAY (naloxone) naloxone cartridge/syringe/vial naloxone nasal spray (OTC) NARCAN NASAL SPRAY (naloxone) REXTOVY NASAL SPRAY (naloxone) SUBLOCADE (buprenorphine solution) <sup>CL/PA</sup>	BUNAVAIL (buprenorphine/naloxone) buprenorphine tablets buprenorphine/naloxone film lofexidine LUCEMYRA (lofexidine)* naloxone nasal spray (Rx) <b>OPVEE (nalmefene)</b> ZIMHI (naloxone hydrochloride)	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
SUBOXONE FILM (buprenorphine/naloxone) VIVITROL (naltrexone)	ZUBSOLV (buprenorphine/naloxone)	
<b>ORAL AND TOPICAL CONTRACEPTIVES</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a trial with three preferred contraceptive products including a trial with a preferred product with the same route of administration as the requested non-preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
AFIRMELLE ALTAVERA AMETHYST APRI AUBRA AUBRA EQ AUROVELA AVIANE AYUNA AZURETTE BALZIVA BEYAZ BLISOVI FE CAMILA CAMRESE 3 MONTH CHATEAL CHATEAL EQ CYRED CYRED EQ DEBLITANE desogestrel-ethinyl estradiol desogestrel-ethinyl estradiol/ethinyl estradiol DOLISHALE drospirenone-ethinyl estradiol ENSKYCE ERRIN ESTARYLLA FALMINA HAILEY FE HEATHER HER STYLE INCASSIA ISIBLOOM	ALYACEN AMETHIA 3 MONTH ARANELLE ASHLYNA 3 MONTH AUROVELA 24 FE AUROVELA FE BALCOLTRA BLISOVI 24 FE BRIELLYN CAMRESE LO 3 MONTH CHARLOTTE 24 FE CHEWABLE TABLETS CRYSELLE CURAE DASETTA DAYSEE 3 MONTH drospirenone-ethinyl estradiol-levomefolate ECONTRA EZ ECONTRA ONE-STEP ELINEST ELLA ENPRESSE ethynodiol-ethinyl estradiol FAYOSIM 3 MONTH FINZALA GEMMILY HAILEY HAILEY 24 FE ICLEVIA 3 MONTH INTROVALE 3 MONTH JAIMIESS 3 MONTH JASMIEL JOYEAUX JUNEL	*Phexxi may be approvable when it is prescribed for the prevention of pregnancy; <b>AND</b> reasoning is provided as to why the clinical need cannot be met with a preferred agent. Phexxi will not be approved for use by patients who are also using hormonal contraceptive vaginal rings.

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
JENCYCLA JOLESSA 3 MONTH JULEBER JUNEL FE KARIVA KURVELO LARIN FE LESSINA LEVONEST levonorgestrel levonorgestrel-ethinyl estradiol levonorgestrel-ethinyl estradiol 3 month (generic LOSEASONIQUE) levonorgestrel-ethinyl estradiol-ferrous bisglycinate LILLOW LO LOESTRIN FE LORYNA LUTERA LYLEQ LYZA MARLISSA MIBELAS 24 FE MICROGESTIN FE MILI MONO-LINYAH MY CHOICE MY WAY NATAZIA NEW DAY NIKKI NORA-BE norethindrone norethindrone-ethinyl estradiol-iron tablets norethindrone-ethinyl estradiol norgestimate-ethinyl estradiol NORLYDA NYLIA	JUNEL FE 24 KAITLIB FE KALLIGA KELNOR 1-35 KELNOR 1-50 LARIN LARIN 24 FE LAYOLIS FE CHEWABLE TABLETS LEENA levonorgestrel-ethinyl estradiol 3 month (generic JOLESSA) LEVORA-28 LOESTRIN LOESTRIN FE LOJAIMIESS 3 MONTH LOSEASONIQUE 3 MONTH LOW-OGESTREL LO-ZUMANDIMINE MERZEE MICROGESTIN MICROGESTIN 24 FE MINASTRIN 24 FE CHEWABLE TABLETS MINZOYA MIRCETTE NECON NEXTSTELLIS norethindrone-ethinyl estradiol-iron capsules norethindrone-ethinyl estradiol-iron chewable tablets NORTREL OPTION 2 PHEXXI VAGINAL GEL* PHILITH PIMTREA QUARTETTE RECLIPSEN RIVELSA 3 MONTH SAFYRAL	

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
NYMYO OCELLA OPCICON ONE-STEP PORTIA SHAROBEL SIMLIYA SPRINTEC SRONYX TARINA FE TARINA FE 1-20 EQ TAYTULLA TRI-ESTARYLLA TRI-FEMYNOR TRI-LINYAH TRI-LO-ESTARYLLA TRI-LO-MARZIA TRI-LO-MILI TRI-LO-SPRINTEC TRI-MILI TRI-NYMYO TRI-SPRINTEC TRI-VYLIBRA TRI-VYLIBRA LO TULANA TWIRLA PATCH VIENVA VIORELE VOLNEA VYLIBRA YASMIN-28 YAZ ZAFEMY PATCH ZOVIA 1-35 ZOVIA 1-35E ZUMANDIMINE	SEASONIQUE 3 MONTH SETLAKIN 3 MONTH SIMPESSE 3 MONTH SLYND SYEDA TARINA 24 FE TAYSOFY TILIA FE TRI-LEGEST FE TRIVORA-28 TURQOZ TYBLUME CHEWABLE TABLETS TYDEMY VELIVET VESTURA VYFEMLA WERA WYMZYA FE CHEWABLE TABLETS XULANE PATCH	
<b>OTIC ANTIBIOTICS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require five-day trials of each preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CIPRO HC (ciprofloxacin/hydrocortisone) ciprofloxacin/dexamethasone CORTISPORIN-TC (colistin/hydrocortisone/neomycin) neomycin/polymyxin/HC solution, suspension ofloxacin	ciprofloxacin ciprofloxacin/fluocinolone OTOVEL (ciprofloxacin/fluocinolone)	
<b>PAH AGENTS<sup>CL/PA</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 30-day trial of a preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
<b>ACTIVIN SIGNALING INHIBITOR</b>		
	WINREVAIR (sotatercept-csrk)*	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>COMBINATIONS</b>		
	OPSYNVI (macitentan/tadalafil)*	*Opsynvi requires review by the Medical Director and is available only on appeal.
<b>ENDOTHELIN RECEPTOR ANTAGONISTS</b>		
bosentan LETAIRIS (ambrisentan)	ambrisentan OPSUMIT (macitentan) TRACLEER SUSPENSION (bosentan)	
<b>GUANYLATE CYCLASE INHIBITORS</b>		
	ADEMPAS (riociguat)*	*Adempas requires a 30-day trial of a preferred agent from any other PAH Class before it may be approved, unless one of the exceptions on the PA form is present.
<b>Pulmonary Arterial Hypertension (PAH) AGENTS – PDE5s</b>		
sildenafil tablets	ADCIRCA (tadalafil) LIQREV (sildenafil)* REVATIO IV (sildenafil) REVATIO TABLETS (sildenafil) sildenafil suspension (generic REVATIO)** TADLIQ SUSPENSION (tadalafil)***	*Liqrev may be authorized for those who are unable to ingest solid dosage forms due to documented oral-motor difficulties or dysphagia <b>AND</b> documentation is provided as to why the clinical need cannot be met with sildenafil suspension.  **Sildenafil suspension may be authorized for those who are unable to ingest solid dosage forms due to documented oral-motor difficulties or dysphagia. ***Tadliq may be authorized for those who are unable to ingest solid dosage forms due to documented oral-motor difficulties or dysphagia <b>AND</b> after a 30-day trial of sildenafil suspension resulting in an inadequate treatment response.
<b>PAH AGENTS – PROSTACYCLINS</b>		
epoprostenol (generic FLOLAN)	FLOLAN (epoprostenol)	*Ventavis will only be authorized for the treatment of

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
epoprostenol (generic VELETRI) VENTAVIS (iloprost)*	ORENITRAM ER (treprostinil) REMODULIN (treprostinil sodium) treprostinil (generic REMODULIN) TYVASO (treprostinil) TYVASO DPI (treprostinil) UPTRAVI (selexipag) VELETRI (epoprostenol)	pulmonary artery hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms.
<b>PANCREATIC ENZYMES<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 30-day trial of a preferred agent before they will be approved, unless one of the exceptions on the PA form is present. For members with cystic fibrosis, a trial of a preferred agent will not be required.		
CREON PERTZYE ZENPEP	VIOKACE	
<b>PITUITARY SUPPRESSIVE AGENTS, LHRH<sup>CL/PA</sup></b>		
<b>CLASS PA CRITERIA:</b> Unless otherwise noted, non-preferred agents are available only on appeal.		
FENSOLVI SYRINGE (leuprolide acetate) LUPANETA (leuprolide) LUPRON DEPOT KIT (leuprolide) LUPRON DEPOT-PED KIT (leuprolide) MYFEMBREE (relugolix/estradiol/norethindrone)* ORILISSA (elagolix)* SYNAREL (nafarelin) TRELSTAR (triptorelin) TRIPTODUR (triptorelin)	leuprolide ORIAHNN (elagolix/estradiol/norethindrone)* SUPPRELIN LA KIT (histrelin)	*Full PA criteria for Myfembree, Orilissa and OriaHnn may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink. In addition, Orilissa and OriaHnn may only be approved if there is a documented side effect, allergy, or treatment failure with Myfembree. Use of GnRH receptor antagonists will be limited to 24 months.
<b>PLATELET AGGREGATION INHIBITORS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 30-day trial of a preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
BRILINTA (ticagrelor) clopidogrel dipyridamole prasugrel ticagrelor 90 mg tablets (Generic BRILINTA 90mg)	clopidogrel kit dipyridamole/aspirin EFFIENT (prasugrel) PLAVIX (clopidogrel) ticagrelor 60 mg tablets (Generic BRILINTA 90mg) ZONTIVITY (vorapaxar)	
<b>POTASSIUM REMOVING AGENTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 30-day trial of a preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
LOKELMA (sodium zirconium cyclosilicate) VELTASSA (patiromer calcium sorbitex)	KIONEX (sodium polystyrene sulfonate) SPS (sodium polystyrene sulfonate)	



THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>PROGESTINS FOR CACHEXIA</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a 30-day trial of a preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
megestrol		
<b>PROTON PUMP INHIBITORS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 60-day trials of both omeprazole (Rx) and pantoprazole at the maximum recommended dose, inclusive of a concurrent 30-day trial at the maximum dose of an H <sub>2</sub> antagonist before they will be approved, unless one of the exceptions on the PA form is present.		
omeprazole (Rx) pantoprazole tablets PROTONIX GRANULES (pantoprazole)*	ACIPHEX (rabeprazole) ACIPHEX SPRINKLE (rabeprazole) DEXILANT (dexlansoprazole) dexlansoprazole DR capsules esomeprazole magnesium KONVOMEF (omeprazole/sodium bicarbonate) lansoprazole (Rx) NEXIUM (esomeprazole) NEXIUM PACKETS (esomeprazole) omeprazole/sodium bicarbonate (Rx) pantoprazole granule packets PREVACID CAPSULES (lansoprazole) PREVACID SOLUTABS (lansoprazole)* PRILOSEC (Rx) (omeprazole) PROTONIX DR TABLETS (pantoprazole) Rabeprazole VOQUEZNA (vonoprazan)** ZEGERID (Rx) (omeprazole/sodium bicarbonate)	*Prior authorization is required for members nine years of age or older for these agents.  **Voquezna (vonoprazan) is NOT a PROTON PUMP INHIBITOR but will remain on the PDL in this class due to similar indications.
<b>SEDATIVE HYPNOTICS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 30-day trials of all preferred agents in <b>BOTH subclasses</b> before they will be approved, unless one of the exceptions on the PA form is present. All agents <u>except melatonin</u> will be limited to 15 tablets in a 30-day period. <b>NOTE:</b> WV Medicaid covers melatonin up to a maximum dose of 9 mg/day without a PA. Melatonin labeler code 51645 is preferred. Please refer to the posted <a href="#">Covered OTC Products</a> for a complete list of payable NDCs.		
<b>BENZODIAZEPINES</b>		
temazepam 15 mg and 30 mg	estazolam flurazepam HALCION (triazolam) RESTORIL (temazepam) temazepam 7.5 mg and 22.5 mg triazolam	
<b>OTHERS</b>		
BELSOMRA (suvorexant)** melatonin ROZEREM (ramelteon) zolpidem 5 mg and 10 mg	AMBIEN (zolpidem) AMBIEN CR (zolpidem) DAYVIGO (lemborexant) doxepin 3 mg and 6 mg	For treatment naïve female patients, zolpidem and zolpidem ER maximum dosages will be limited to 5 mg and 6.25 mg respectively per day.

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	EDLUAR (zolpidem) eszopiclone HETLIOZ (tasimelteon) <sup>CL*</sup> LUNESTA (eszopiclone) QUVIVIQ (daridorexant) ramelteon SILENOR (doxepin) tasimelteon zaleplon zolpidem ER 6.25 mg and 12.5 mg	<p>*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.</p> <p>**Belsomra may be approved after a trial of zolpidem or temazepam, unless one of the exceptions on the PA form is present.</p>
<b>SKELETAL MUSCLE RELAXANTS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> See below for individual subclass criteria.		
<b>ACUTE MUSCULOSKELETAL RELAXANT AGENTS</b>		
chlorzoxazone (generic PARAFON FORTE) cyclobenzaprine IR 5 mg and 10 mg methocarbamol	AMRIX (cyclobenzaprine) carisoprodol* carisoprodol/ASA* carisoprodol/ASA/codeine* chlorzoxazone (generic LORZONE) cyclobenzaprine ER cyclobenzaprine IR 7.5 mg FEXMID (cyclobenzaprine) LORZONE (chlorzoxazone) metaxalone orphenadrine orphenadrine ER ROBAXIN (methocarbamol) SKELAXIN (metaxalone) SOMA (carisoprodol)* TANLOR (methocarbamol)	<p>Non-preferred agents require 30-day trials of each preferred agent before they will be approved, unless one of the exceptions on the PA form is present, with the exception of carisoprodol.</p> <p>*Carisoprodol requires 30-day trials of each of the preferred acute musculoskeletal relaxants and metaxalone before it will be approved.</p>
<b>MUSCULOSKELETAL RELAXANT AGENTS USED FOR SPASTICITY</b>		
baclofen tizanidine tablets	baclofen solution*, suspension DANTRIUM (dantrolene) dantrolene FLEQSUVY SUSPENSION (baclofen)* LYVISPAH GRANULE PACKETS (baclofen)* tizanidine capsules ZANAFLEX (tizanidine)	<p>Non-preferred agents require 30-day trials of each preferred agent before they will be approved, unless one of the exceptions on the PA form is present.</p> <p>*Oral baclofen solution/suspension, Fleqsuvy suspension and Lyvispah granules may only be authorized for those who are unable to ingest solid dosage forms due to documented oral-motor difficulties or dysphagia.</p>
<b>STERIODS, TOPICAL</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require five-day trials of one form of <b>EACH</b> preferred unique active ingredient in the corresponding potency group before they will be approved, unless one of the exceptions on the PA form is present.		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>VERY HIGH &amp; HIGH POTENCY</b>		
betamethasone dipropionate cream betamethasone valerate cream betamethasone valerate lotion betamethasone valerate ointment clobetasol emollient clobetasol propionate cream, gel, ointment, solution clobetasol propionate shampoo fluocinonide gel triamcinolone acetonide cream, ointment triamcinolone acetonide lotion	amcinonide APEXICON E (diflorasone diacetate) betamethasone dipropionate gel, lotion, ointment clobetasol lotion clobetasol propionate foam, spray CLODAN KIT (clobetasol propionate) CLODAN SHAMPOO (clobetasol propionate) desoximetasone cream, gel, ointment, spray diflorasone diacetate DIPROLENE (betamethasone dipropionate/propylene glycol) fluocinonide cream fluocinonide ointment fluocinonide solution fluocinonide/emollient halcinonide cream halobetasol propionate IMPEKLO LOTION (clobetasol propionate) KENALOG (triamcinolone acetonide) LEXETTE FOAM (halobetasol) OLUX (clobetasol propionate) OLUX-E (clobetasol propionate emulsion) PSORCON (diflorasone diacetate) TEMOVATE (clobetasol propionate) TOPICORT CREAM, GEL, OINTMENT (desoximetasone) TOPICORT SPRAY (desoximetasone) TOVET FOAM (clobetasol) ULTRAVATE (halobetasol propionate) ULTRAVATE PAC cream	
<b>MEDIUM POTENCY</b>		
fluticasone propionate cream, ointment mometasone furoate triamcinolone acetonide 0.025% and 0.1% cream	BESER LOTION (fluticasone) betamethasone valerate foam clocortolone cream CORDRAN (flurandrenolide) CUTIVATE (fluticasone propionate) fluocinolone acetonide cream, ointment, solution flurandrenolide cream, lotion, ointment fluticasone propionate lotion hydrocortisone butyrate cream hydrocortisone butyrate ointment, solution hydrocortisone valerate	

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	LUXIQ (betamethasone valerate) PANDEL (hydrocortisone probutate) prednicarbate	
LOW POTENCY		
fluocinolone oil hydrocortisone acetate (Rx, OTC) hydrocortisone cream (Rx, OTC) hydrocortisone lotion hydrocortisone ointment (Rx, OTC) hydrocortisone solution (OTC) hydrocortisone-aloe cream (OTC) hydrocortisone-aloe ointment (OTC)	alclometasone dipropionate AQUA GLYCOLIC HC (hydrocortisone) DERMA-SMOOTH FS (fluocinolone acetonide) DESONATE (desonide) desonide cream, ointment desonide lotion hydrocortisone/mineral oil/petrolatum hydrocortisone acetate/urea hydrocortisone/aloe gel SCALPICIN (OTC) (hydrocortisone) SYNALAR (fluocinolone) TEXACORT (hydrocortisone)	
<b>STIMULANTS AND RELATED AGENTS</b>		
<b>CLASS PA CRITERIA:</b> A prior authorization is required for adults 18 years of age or older. Non-preferred agents require a 30-day trial of at least one preferred agent in the same subclass and with a similar duration of effect and mechanism of action, unless one of the exceptions on the PA form is present. <b>NOTE:</b> Children under 18 years of age may continue their existing therapy at the discretion of the prescriber.		
AMPHETAMINES		
ADDERALL XR (amphetamine salt combination) amphetamine salt combination ER amphetamine salt combination IR dextroamphetamine ER dextroamphetamine IR DYANAVEL XR SUSPENSION (amphetamine) PROCENTRA SOLUTION (dextroamphetamine) VYVANSE CAPSULES (lisdexamfetamine)	ADDERALL (amphetamine salt combination) ADZENYS XR ODT (amphetamine) ADZENYS ER SUSPENSION (amphetamine) amphetamine tablets DESOXYN (methamphetamine) DEXEDRINE ER (dextroamphetamine) dextroamphetamine solution DYANAVEL XR TABLETS (amphetamine) EVEKEO (amphetamine) EVEKEO ODT (amphetamine) lisdexamfetamine capsules, chewable methamphetamine MYDAYIS (dextroamphetamine/amphetamine salt)* (lisdexamfetamine) VYVANSE CHEWABLE TABLETS (lisdexamphetamine) XELSTRYM PATCHES (dextroamphetamine) ZENZEDI (dextroamphetamine)	<b>In addition to the Class Criteria:</b> 30-day trials of at least three antidepressants are required before amphetamines will be authorized for depression.  *Mydayis requires a 30-day trial of at least one long-acting preferred agent in this subclass and a trial of Adderall XR.
NON-AMPHETAMINE		
atomoxetine*	ADHANSIA XR (methylphenidate)	*Strattera is limited to a maximum of 100 mg per day.

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
clonidine IR clonidine ER CONCERTA (methylphenidate) dexamethylphenidate IR dexamethylphenidate XR guanfacine ER guanfacine IR methylphenidate IR methylphenidate CD capsules methylphenidate ER 24 tablets (generic CONCERTA) methylphenidate ER tablets (generic RITALIN SR) methylphenidate ER CD capsules methylphenidate solution QUILLICHEW ER (methylphenidate) QUILLIVANT XR (methylphenidate) RITALIN LA (methylphenidate)	APTENSIO XR (methylphenidate) AZSTARYS (dexamethylphenidate/serdexmethylphenidate) COTEMPLA XR ODT (methylphenidate) DAYTRANA (methylphenidate) FOCALIN IR (dexamethylphenidate) FOCALIN XR (dexamethylphenidate) INTUNIV (guanfacine ER) JORNAY PM (methylphenidate) METHYLIN SOLUTION (methylphenidate) methylphenidate chewable tablets methylphenidate ER capsules methylphenidate ER 72 mg tablets methylphenidate ER LA capsules methylphenidate LA capsules methylphenidate patches ONYDA XR (clonidine) QELBREE (viloxazine)** RELEXXII (methylphenidate ER) RITALIN (methylphenidate) STRATTERA (atomoxetine)*	**Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
NARCOLEPTIC AGENTS		
armodafinil* modafinil*	NUVIGIL (armodafinil)* PROVIGIL (modafinil)* sodium oxybate* SUNOSI (solriamfetol)** WAKIX (pitolisant)*** XYREM (sodium oxybate)* XYWAV (calcium/magnesium/potassium/sodium oxybate)*	*Full PA criteria for narcoleptic agents, Xyrem/Xywav may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.  **Sunosi is approvable only with documentation of treatment failure after 30-day trials of both armodafinil and modafinil. ***Wakix is approvable only with documentation of treatment failure after 30-day trials of armodafinil, modafinil and Sunosi.
TETRACYCLINES		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 10-day trials of each preferred agent before they will be approved, unless one of the exceptions on the PA form is present.		
doxycycline hyclate capsules doxycycline hyclate 100 mg tablets doxycycline monohydrate 50 mg and 100 mg capsules minocycline capsules tetracycline capsules	demeclocycline** DORYX (doxycycline hyclate) doxycycline hyclate 50 mg, 75 mg and 150 mg tablets doxycycline hyclate DR 75 mg, 100 mg, 150 mg and 200 mg tablets doxycycline hyclate DR 50 mg tablets	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.  **Demeclocycline will be authorized for conditions caused by susceptible strains of organisms designated in the product information supplied by the manufacturer.

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	doxycycline monohydrate 40 mg, 75 mg and 150 mg capsules doxycycline monohydrate tablets doxycycline monohydrate suspension MINOCIN (minocycline) minocycline ER capsules minocycline tablets MINOLIRA ER (minocycline) MORGIDOX KIT (doxycycline) NUZYRA (omadacycline)* tetracycline tablets VIBRAMYCIN CAPSULES, SUSPENSION, SYRUP (doxycycline) XIMINO (minocycline)	A Culture and Sensitivity (C&S) report must accompany this request. Demeclocycline will also be authorized for Syndrome of Inappropriate Antidiuretic Hormone (SIADH).
<b>ULCERATIVE COLITIS AGENTS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 30-day trials of each preferred dosage form or chemical entity before the corresponding non-preferred agent of that dosage form or chemical entity will be approved, unless one of the exceptions on the PA form is present.		
<b>ORAL</b>		
balsalazide PENTASA 250 mg (mesalamine) PENTASA 500 mg (mesalamine) sulfasalazine	AZULFIDINE (sulfasalazine) budesonide ER tablets DIPENTUM (olsalazine) LIALDA (mesalamine) mesalamine ZEPOSIA (ozanimod)	
<b>RECTAL</b>		
mesalamine	mesalamine kit ROWASA (mesalamine) SF ROWASA (mesalamine)	
<b>VAGINAL RING CONTRACEPTIVES</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred drugs require medical reasoning beyond convenience or enhanced compliance as to why the clinical need cannot be met with a preferred agent.		
ELURYNG (etonogestrel/ethinyl estradiol) ENILLORING (etonogestrel/ethinyl estradiol) etonogestrel/ethinyl estradiol vaginal ring HALOETTE (etonogestrel/ethinyl estradiol) NUVARING (etonogestrel/ethinyl estradiol)	ANNOVERA (segesterone/ethinyl estradiol)	
<b>VASODILATORS, CORONARY</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 30-day trials of each preferred dosage form before they will be approved, unless one of the exceptions on the PA form is present.		

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>SUBLINGUAL NITROGLYCERIN</b>		
nitroglycerin spray (generic NITROLINGUAL) nitroglycerin sublingual NITROSTAT SUBLINGUAL (nitroglycerin)	GONITRO SPRAY POWDER (nitroglycerin) nitroglycerin spray (generic NITROMIST) NITROLINGUAL SPRAY (nitroglycerin) NITROMIST (nitroglycerin)	
<b>TOPICAL NITROGLYCERIN</b>		
MINITRAN PATCHES (nitroglycerin) NITRO-BID OINTMENT nitroglycerin patches	NITRO-DUR PATCHES (nitroglycerin)	
<b>VMAT INHIBITORS</b>		
<b>CLASS PA CRITERIA: All agents require a prior authorization.</b> Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.		
AUSTEDO TABLETS (deutetrabenazine) AUSTEDO XR (deutetrabenazine) INGREZZA CAPSULES (valbenazine) INGREZZA SPRINKLE CAPSULES (valbenazine) tetrabenazine tablets	XENAZINE TABLETS	
<b>MISCELLANEOUS COVERED AGENTS</b>		
<b>This category contains covered agents which either did not easily fit into a single PDL category or had criteria that was too lengthy to cite within the PDL itself. Full criteria for the agents listed below may be found by following this link: (<a href="https://bms.wv.gov/page/prior-authorization-criteria">https://bms.wv.gov/page/prior-authorization-criteria</a>) Please note that some agents may be available only by billing the appropriate HCPCS code noted in the criteria.</b>		
Abecma Adbry Afinitor Albenza and Emverm Alyftrek Amondys 45 Antifungal Agents Atypical Antipsychotic Agents for Children up to 18 years of age Austedo Belbuca Benlysta Botox Breyanzi Cabenuva Camzyos Carbaglu Carvykti Casgevy CGRP Receptor Antagonists (antimigraine agents, prophylaxis) Cibinqo Continuous Glucose Monitors		

Corlanor  
Cresemba  
Cuvposa  
Cytokine & CAM Antagonists  
Diclegis  
Dificid  
Dojolvi  
Droxidopa  
Duavee  
Dupixent  
Elevidys  
Emflaza  
Enspryng  
Esbriet  
Evrysdi  
ExJade  
Exondys 51  
Fasenra  
Feriprox  
Fintepla  
Fuzeon  
Gattex  
Growth Hormone for Adults  
Growth Hormone for Children  
Hepatitis C  
Hereditary Angioedema Agents (prophylaxis)  
Hereditary Angioedema Agents (treatment)  
Hetlioz  
Home Infusion Drugs and Supplies  
Horizant  
HP Acthar  
HyQvia  
Increlex  
Ingrezza  
Jublia  
Juxtapid  
Kalydeco  
Kerendia  
Ketoconazole  
Korlym  
Kuvan  
Kymriah  
Kynamro  
Leqvio  
Lucemyra  
Lutathera  
Lupkynis  
Luxturna



Lyfgenia  
Mozobil  
Myalept  
Myfembree  
Mytesi  
Narcoleptic Agents  
Natpara  
Nemluvio  
Nexletol and Nexlizet  
Non-Sedating Antihistamines  
Nucala  
Nuzyra  
OFEV  
Omnipod  
Opzelura  
Orilissa  
Oralair  
OriaHnn  
Orkambi  
Osphena  
Oxlumo  
Palynziq  
PCSK9 Inhibitor  
Qelbree  
Rectiv  
Riluzole  
Rinvoq  
Risperdal Consta  
Sirturo  
Spinraza  
Spravato  
Suboxone Policy  
Symdeko  
Synagis  
Testosterone  
Tezspire  
Thalomid  
Trikafta  
Tryvio  
V-Go  
Veozah  
Verquvo  
Viberzi and Lotronex  
Vowst  
Voxzogo  
Vyondys 53  
Wegovy  
Winrevair  
Xanax XR

Xenazine  
Xhance  
Xolair  
Xyrem and Xywav  
Yescarta  
Zepbound  
Zolgensma  
Zulresso  
Zurampic  
Zurzuvae  
Zynteglo  
Zyvox

DRAFT